



Review

Insights on Dietary Polyphenols as Agents against Metabolic Disorders: Obesity as a Target Disease

Simon-Okomo Aloo ¹, Fred Kwame Ofosu ¹, Nam-Hyeon Kim ¹, Sheila M. Kilonzi ² and Deog-Hwan Oh ^{1,*}

¹ Department of Food Science and Biotechnology, College of Agriculture and Life Sciences, Kangwon National University, Chuncheon 24341, Republic of Korea

² Department of Food Science and Nutrition, School of Agriculture and Biotechnology, Karatina University, Karatina 10101, Kenya

* Correspondence: deoghwa@kangwon.ac.kr

Abstract: Obesity is a condition that leads to increased health problems associated with metabolic disorders. Synthetic drugs are available for obesity treatment, but some of these compounds have demonstrated considerable side effects that limit their use. Polyphenols are vital phytonutrients of plant origin that can be incorporated as functional food ingredients. This review presents recent developments in dietary polyphenols as anti-obesity agents. Evidence supporting the potential application of food-derived polyphenols as agents against obesity has been summarized. Literature evidence supports the effectiveness of plant polyphenols against obesity. The anti-obesity mechanisms of polyphenols have been explained by their potential to inhibit obesity-related digestive enzymes, modulate neurohormones/peptides involved in food intake, and their ability to improve the growth of beneficial gut microbes while inhibiting the proliferation of pathogenic ones. Metabolism of polyphenols by gut microbes produces different metabolites with enhanced biological properties. Thus, research demonstrates that dietary polyphenols can offer a novel path to developing functional foods for treating obesity. Upcoming investigations need to explore novel techniques, such as nanocarriers, to improve the content of polyphenols in foods and their delivery and bioavailability at the target sites in the body.

Keywords: anti-obesity; bioavailability; functional ingredient; gut microbiota; safety



Citation: Aloo, S.-O.; Ofosu, F.K.; Kim, N.-H.; Kilonzi, S.M.; Oh, D.-H. Insights on Dietary Polyphenols as Agents against Metabolic Disorders: Obesity as a Target Disease.

Antioxidants **2023**, *12*, 416.

<https://doi.org/10.3390/antiox12020416>

Academic Editors: Simone Carradori and Andrei Mocan

Received: 28 January 2023

Revised: 2 February 2023

Accepted: 2 February 2023

Published: 8 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Obesity results from the excessive accumulation of body fat due to an imbalance between energy intake and expenditure. Obesity is a risk factor for several other chronic disorders, including type 2 diabetes mellitus, cardiovascular diseases, stroke, dementia, osteoarthritis, and breast, colon, and prostate cancers [1,2]. It can contribute to a decline in life quality and expectancy and may also lead to many other psychological problems. Modifying lifestyle is considered the most appropriate approach to reducing obesity [1]. In particular, adjusting an individual's diet to include healthier foods is vital in weight management. Globally, obesity is constantly growing in prevalence and significance, posing a threat to health. Once just a problem of wealthy nations, obesity now impacts more countries at all economic levels, bringing with it a wave of ill health and loss of productivity among the population. The worldwide prevalence of the disease has doubled since the beginning of 1980 [3]. Today, obesity is considered one of the most serious public health concerns, with the latest figures from the World Health Organization's database showing that about one in ten young people, ages 5–17, are overweight or obese, while the condition is even severe among middle-aged people [3]. Bariatric surgery and synthetic drugs (such as orlistat and naltrexone/bupropion, glucagon-like peptide-1 receptor agonists) have been accepted as therapeutic strategies for obesity. However, these treatment methods have been associated with unpleasant side effects that limit their use [4]. As a result of these concerns, other alternative approaches are needed to help fill this gap and reduce

the impact of obesity among the population. This challenge has led to more research on obesity, including assessing the effect of polyphenols on disease. Polyphenols are vital phytonutrients of plant origin that can be incorporated as functional ingredients in foods to offer an effective natural therapy against obesity. There have been efforts to discover alternative obesity treatments from dietary polyphenols [1,2]. Although several other papers have been on this subject, the current article reviewed the most current knowledge on the relationship between plant-derived polyphenols and obesity. The cellular, animal, and human data supporting the anti-obesity potential of phenolic compounds have been summarized. The information presented in the review is unique in revealing the potential role of polyphenols in weight management and their safety-related issues. The article offers the most comprehensive evidence, combining the incorporation of polyphenols into foods, safety aspects, bioavailability, and related research limitations in preclinical and clinical studies in an attempt to provide a lead for more studies regarding foods targeting obesity. However, this article has some weaknesses as described in Figure 1.




Figure 1. Strengths and weaknesses of the current article.

2. Existing Treatment for Obesity and Their Safety Limitations

The existing methods of obesity management include surgical procedures, administration of synthetic drugs, and diet and exercise. The combination of diet and exercise is considered the safest and most appropriate method for weight management. Bariatric surgery refers to various surgical procedures that alter the anatomy of the gastrointestinal tract [4]. Even though it is an effective method of obesity treatment, the cost of bariatric surgery is high, and its post-surgery care is a burden to most patients [4]. In addition, the procedure is associated with various risks of developing acute kidney injury, marginal ulcers, and gallstones [4].

On the other hand, drug therapy is an adjunct to diet and exercise in people who require more advanced intervention. The current anti-obesity drugs aim to reduce food intake by either curbing appetite or suppressing the craving for food. Conventional anti-obesity drugs exert anorectic action due to their effects on the levels of monoamines in various brain nuclei [5]. However, in addition to their anorexic effects, these drugs have been linked to altered brain functions associated with sexual behavior, hormonal secretion, mood, and sleep, among other neuro-related effects [5]. In addition to associated neuro influences, some of these compounds, such as orlistat, have been linked with gastroin-

testinal and cardiovascular side effects such as steatorrhea, fecal incontinence, flatulence, and malabsorption of fat-soluble vitamins, making their use limited [5]. To overcome the challenges arising from the use of orlistat, a new pancreatic lipase inhibitor, cetilistat, was developed [6]. Cetilistat has been found to show considerable potential in the treatment of obesity; nonetheless, evidence from in vivo studies indicates that the gastrointestinal effects can persist even with the use of cetilistat [6].

There is also ongoing research on developing anti-obesity treatments based on the two incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Treating diseases by administering agonists of GIP and GLP-1 exploits their physiological effects on the body [7]. These compounds may demonstrate anti-obesity effects by engaging endogenous hormones involved in energy balance and metabolism [7], although they, too, have several limitations (Table 1). Consequently, there is a substantial unmet need to find effective and safer anti-obesity management methods; research is still needed on natural plant metabolites such as polyphenols to help understand their anti-obesity efficacy

Table 1. Safety of anti-obesity drugs in clinical studies.

Drug	Country	Participants	Dose	Reported Adverse Effect	References
Common Drugs					
<i>For short-term use</i>					
Diethylpropion	Brazil	N = 69	50 mg per day for 6 months	Dry mouth and insomnia	[8]
Mazindol	USA	N = 85	1–3 mg per day for 6 weeks.	Dry mouth, nausea, decreased appetite, fatigue, heart rate, and constipation	[9]
Phendimetrazine	USA	N = 13	140–210 mg per day for 7-days	No observable adverse effects	[10]
Phentermine	Korea	N = 74	30 mg per day for 12 weeks	Dry mouth and insomnia	[11]
<i>For long-term use</i>					
Orlistat	Japan	N = 100	60 mg three times daily for 24 weeks	Oily spotting and flatus with discharge	[12]
Topiramate ER	Canada, Europe and South Africa	N = 646	192 mg per day for 24 weeks.	Paresthesia and central nervous system-related effects.	[13]
Lorcaserin	USA	N = 604	10 mg per day for 12 months	Headache, nasopharyngitis, nausea, and back pain	[14]
Sibutramine	USA	N = 61	20 mg once daily for 12 weeks	No adverse effect	[15]
Naltrexone/Bupropion ER	USA	N = 1650	Naltrexone 32 mg per day plus bupropion 360 mg per day 56 weeks	Headache, constipation, nausea, dizziness, vomiting, and dry mouth	[16]
GLP-1 receptor agonists					
<i>For short-term use</i>					
Exenatide	China	N = 681	2 mg per day for 10 weeks	Nausea, dyslipidemia, and vomiting	[17]
Lixisenatide	France	N = 484	20 µg per day for 24 weeks	Acute pancreatitis	[18]
<i>For long-term use</i>					
Liraglutide,	Australia, Belgium, the UK, the USA, Russia, Israel, and Germany	-	30 mg per day for 52 weeks	Gastrointestinal symptoms, primarily nausea	[19]
Albiglutide	USA	N = 155	30 mg per week for 52 weeks	Diarrhea, nausea, and vomiting	[20]
Dulaglutide	Not reported	N = 807	1.5 mg or 0.75 mg per day for 52 weeks	Nausea, diarrhea, and vomiting	[21]

3. Diversity of Polyphenols in Diet and Their Biological Significance

Polyphenols are compounds with several hydroxyl groups on an aromatic ring. Most of these compounds can be found in several plant foods, including tea leaves, cereals, legumes, and fruits, while some are mainly associated with specific foods (e.g., isoflavones in soya, phloridzin in apples, flavanones in citrus, etc.). They can be grouped into two broad categories: flavonoid-type and non-flavonoid-types with distinct structures (Figure 2). These groups are discussed below.




Figure 2. Structures of flavonoids and Non-flavonoids polyphenols.

3.1. Flavonoid-Type Phenolic Compounds

Flavonoid-type phenolic compounds are further grouped into subclasses of flavanols, flavonols, isoflavones, flavanones, anthocyanins, and proanthocyanidins. **Flavonols** are the groups of polyphenols containing a 3-hydroxyflavone base (3-hydroxy-2-phenylchromen-4-one) on their structure. They are distinguished from other polyphenols by hydroxy modification at distinct positions of the phenol residue [22]. Foods with specified amounts of these compounds but lacking other active ingredients have demonstrated strong anti-obesity effects [23]. Green tea rich in flavonols may reduce obesity through their thermogenic effect and increased fat oxidation [23]; they can also inhibit enzymes involved in fat synthesis [23]. **Flavones** have a basic structure consisting of a 2-phenyl-benzo- γ -pyrone skeleton formed by two phenyl rings (A and B) linked with a heterocyclic pyrone ring [22]. They are said to have relatively higher bioavailability in the body compared to flavonols, probably because of degradation by gut microbiota and greater accessibility for absorption in the intestine [22]. Flavones such as ellagitannins and granatin B present in the edible flowers of *Punica granatum* L. were reported to exert a potent anti-obesity potential when consumed [24]. The large numbers of hydroxyl groups on the flavone molecule are responsible for their α -glucosidase, α -amylase, and lipase inhibitory activities, which is the anti-obesity mechanism of their action [24].

Isoflavones are differentiated from other flavonoids with their planar ring system containing benzenoid B ring attached to carbon number three (C3). Isoflavone-rich foods such as lentils, black soybean, chickpea, peanut, and common beans may demonstrate anti-obesity effects and suppressive ability against oxidation and inflammation associated with obesity [25]. **Anthocyanins** may include and are not limited to delphinidin 3-*O*-rutinoside, malvidin, cyanidin 3-*O*-rutinoside, and cyanidin 3-*O*-glucoside. Food products rich in these compounds, such as wine, berries, and beans, have beneficial effects on obesity [25]. Anthocyanins effectively improve the lipid profile by significantly reducing serum triglyceride and cholesterol levels but increasing high-density lipoprotein-cholesterol concentration in obese conditions [25]. Finally, **flavonols** such as (+)-catechin, (−)-epicatechin, epigallocatechin, and some polymeric procyanidins can be found mostly in fruits, tea, wine and chocolate. They contain a B-ring attached to carbon number two (C2), even though

they lack a carbonyl group in their carbon number four (C4) position or double bonds between carbon number two (C2) and number three (C3). Catechin-rich tea suppressed the expression of miR-335 in white adipose tissue [26]. At the same time, proanthocyanin-rich grape seed extracts administered to rats significantly improved obesity parameters [27], proving their efficacy as anti-obesity agents.

3.2. Non-Flavonoid-Type Phenolic Compounds in Foods

Non-flavonoid polyphenols are diverse in foods. They are categorized into phenolic acids, lignans, and stilbenes. **Phenolic acids** are widely distributed in foods and can be found in high concentrations in grains, wine and berries. They may include and are not limited to caffeic acid, caftaric acid, ferulic acid, chlorogenic acid, and benzoic acid. Many physicochemical factors such as polarity, plant matrix, digestibility by gastrointestinal enzymes, and molecular mass can affect their bio-accessibility and bioavailability. Foods with high phenolic acid content have beneficial effects against obesity, primarily via modulating gut microbiota composition [22]. On the other hand, **lignans** consist of compounds with 1,4-diarylbutane in their structure. They include pinoresinol, secoisolariciresinol, syringaresinol, matairesinol, and lariciresinol diphenolic. These compounds are mainly found in fruits, vegetables, coffee, tea, and cereal products. When consumed, lignans express anti-obesity activity by inhibiting the expression of adipogenic factors and lipid metabolism-regulating factors during adipocyte differentiation [28]. They are also said to be involved in inducing G0/G1 cell cycle arrest, inhibiting mitotic clonal expansion during the early stage of adipogenesis [28]. The bioavailability of lignans requires biotransformation reactions involving demethylation and dehydroxylation, which are directly dependent on intestinal bacterial metabolism [22]. Moreover, **stilbenoids** may be found in red grapes, cranberries, strawberries, and peanuts [22]. Resveratrol and its derivatives are the most known stilbenoids in the diet and probably the most significant and widely studied stilbenoids. Their metabolized form, such as dihydroresveratrol and 3,4'-dihydroxy-trans-stilbene (from trans-resveratrol), are responsible for their anti-obesity effects.

4. Integrating Polyphenols as Bioactive Ingredients in Foods: Foods for Weight Loss

Phenolic compounds are broadly present in the plant kingdom and are arguably the most abundant and essential group of secondary metabolites in plants. Phenols from edible vegetables, cereals, legumes, and fruits are the most consumed dietary polyphenols. Consuming these foods or their products can potentially benefit patients suffering from obesity in disease management. The strategies to control body weight by incorporating active compounds capable of limiting the bioavailability of fats, stimulating energy expenditure, and modifying the composition of the gut microbiota into food products is envisaged as an appropriate method to find alternative treatment for obesity from natural products. There is a growing trend of incorporating bioactive polyphenols with anti-obesity effects into foods to treat and prevent obesity and other diseases [29]. Using food enrichment, encapsulation, and formulation technologies can deliver active ingredients such as polyphenols in processed foods and improve the effectiveness of such foods against obesity [29]. Manipulating products by adding plant bioactive metabolites has become a promising approach for controlling or treating obesity. Such efforts have been successful in producing products such as fruit smoothies with high concentrations of added fruit polyphenols [30], functional bread enriched with fruit polyphenols [31], application of microencapsulation for the safe delivery of green tea polyphenols in foods [32], infant food products such as fruit-based food (from blueberry, cranberry, chokecherry-rich polyphenols) for preventing/treating obesity [33], and drinking yogurt with added fruit polyphenols [33]. In addition to inhibiting obesity development, polyphenol-enriched foods have been stated to prevent obesity-associated disorders. Kiss et al. produced noodles fortified with polyphenol-rich buckwheat and amaranth powders [34]. The antioxidant potential of the fortified product was found to be higher than the control [34]. Mayneris-Perxachs et al. also demonstrated that the supplementation of hesperidin and naringenin in biscuits positively influenced

metabolic syndrome in obese rats [35]. They observed reduced body weight, total body fat, total cholesterol, and oxidative stress [35]. Incorporating polyphenols has positive effects in improving the anti-obesity metabolic properties of foods, and consuming such foods has protective effects against the development and progression of obesity. These benefits have been described in Table 2.

Table 2. Polyphenol-enriched food products targeting obesity.

Polyphenol-Rich Extract	Enriched Product	Experimental Model	Main Observation	References
A mixture of polyphenol-rich extracts from green tea, grape seed, and baobab fruit	White bread	Clinical trial	Improved insulin sensitivity	[36]
Catechins, chlorogenic acids, and hydroxytyrosol	Cooked ham	In vivo	Decreased fat accumulation (23.08% reduction)	[37]
Extracts of pomegranate peels and pomegranate peels (rich in ellagitannins, gallic acid, and ellagic acid)	Cookies	In-vitro	Inhibited α -glucosidase, α -amylase, and lipase activities	[38]
Green tea extract (containing catechins)	Bread	Clinical trial	Improved body weight, waist circumference	[39]
Green tea polyphenols	Bread	In vivo	Significantly suppressed body weight gain	[40]
Proanthocyanidins from carob fruit extract	Meat	In vivo	Decreased accumulation of liver fats	[41]
Polymerized-polyphenol extract from oolong tea	Oolong tea	Clinical trial	Improved body lipid accumulation	[42]

The table describes the polyphenol-enriched food products developed to target obesity in either experimental animal or human clinical trials. The effect of the foods on obesity parameters was evaluated following the intake of polyphenol-enriched.

5. Molecular Target and Mode of Action for Antiobesity of Polyphenols

The mechanisms through which polyphenols can inhibit obesity include inhibiting digestive enzymes (mainly alpha-glucosidase, pancreatic lipase, fatty acid synthase, and alpha-amylase), stimulating energy expenditure, suppressing appetite, regulating lipid synthesis, and modulation of gut microbiota (Figure 3). These mechanisms may occur individually or in certain combinations, as described below.




Figure 3. Molecular target and mode of action for antiobesity of polyphenols. ↑, Up-regulation; ↓, down-regulation.

5.1. Polyphenols Influence Neuropeptides/Hormones Involved in Food Intake and Satiety

There is increasing evidence showing that dietary polyphenols are beneficial in reducing obesity by acting on various neurohormones in the brain involved in food intake and satiety. In vitro and in vivo studies reveal that polyphenols have potential roles in neurohormones that modulate food intake and energy regulation in obesity. Insulin is an important hormone that regulates blood glucose levels in the body; it is adipocytes' primary hormonal signal for energy storage [43]. The causal links between obesity and insulin are complex and controversial, and research has not been able to establish these links fully. However, insulin hypersecretion by the pancreas has been implicated in obesity development and pathogenesis [43]. Studies have been conducted to assess the relationship between insulin and obesity development. For instance, a study indicated that adults who hypersecreted insulin in response to an intravenous glucose tolerance test showed excessive weight gain over a 15-year follow-up period [44]. Thus, insulin is an essential neurohormone in the pathogenesis of obesity, and therefore, reports on the effects of polyphenols on insulin underscore their potential role in obesity. Long-term intracerebroventricular infusion of resveratrol normalized hyperglycemia and improved hyperinsulinemia in obese mice [45]. Down-regulation of the insulin-like growth factor pathway in medulloblastoma cells was observed upon administration of curcumin [46]. The study suggested that curcumin contains polyphenol metabolites which are influential in the central nervous system's effects

in regulating neurohormones such as insulin [46]. Hormone leptin also plays a crucial role in obesity. Adipose tissue is one of the main organs producing several adipokines, such as leptin regulating energy metabolism. Leptin inhibits neuropeptide Y (NPY), which is orexigenic and stimulates proopiomelanocortin which activates anorexigenic factors inhibiting food intake [47]. The daily consumption of 200 mg/kg of resveratrol restored leptin sensitivity in obese rats and reduced their overall body weight [48]. In addition to their effects on insulin and leptin, polyphenols have been shown to exert anti-obesity by directly modulating neuropeptides in food intake, as anthocyanins were reported to inhibit neuropeptide Y, suppressing obesity in high-fat diet-fed rats [49].

5.2. Polyphenols Inhibit Pro-Obesity Enzymes

Ingested fats are metabolized and absorbed in the blood through the duodenum. Lipids exist in the body as triglyceride, an ester compound synthesized from a single molecule of glycerol and three fatty acids. Triglycerides cannot be absorbed into the blood in their native form; they must be hydrolyzed into simpler components (monoacylglycerol and free fatty acids) which can easily be absorbed and transported [50]. Human pancreatic lipase is the main enzyme that breaks down dietary fats in the human digestive system [50]. Therefore, an essential target for the treatment of obesity includes the development of pancreatic lipase inhibitors. Polyphenol-rich extracts from a range of plants have been studied for their ability to inhibit pancreatic lipase activity *in vitro* and *in vivo* [50]. Buchholz et al. reported that several factors determine the inhibitory effect of polyphenols against pancreatic lipase [50]. First, the potential inhibitory ability depends on the number and position of phenolic hydroxyl groups; polyphenols with a higher number of phenolic hydroxyl groups possess a more significant inhibitory effect against pancreatic lipase [50]. Second, non-esterified polyphenols such as (+)-catechin and (–)-epicatechin have been found to possess a lower inhibitory activity than esterified ones [50]. Third, the degree of polymerization of polyphenols influences their ability to inhibit lipase. The investigation of phenolic acids demonstrated that hydroxybenzoic acids inhibit the activity of lipase less powerfully than hydroxycinnamic acids, probably due to their differences in the degree of polymerization [50]. Finally, Buchholz and Melzig deduced that polyphenols with methoxy groups in the molecule are less potent than those with hydroxyl groups. Polyphenols inhibit pancreatic lipase by binding to the protein moiety [50]. Therefore, the protein-binding affinity of polyphenols is vital in the lipase-inhibitory activity of these compounds [51]; possibly the reason polyphenols with different structures have different lipase-binding affinities. Nonetheless, even though polyphenols may prevent the digestion of lipids by lipase enzymes, it has been reported that as the inhibitory activity of polyphenols proceeds, the lipase enzyme activity would often be compensated by increased secretion of these enzymes in the gut [52]. This phenomenon was observed in a study of condensed tannins in rats [52]. Supplementary Table S1 summarizes research on lipase inhibitory activities of polyphenols and polyphenol-rich extracts.

In most cases, obesity occurs when fat synthesis exceeds fat oxidation. In the body, fat accumulation is tightly maintained through lipogenesis and lipolysis. While lipogenesis converts simple sugars and other substrates to fatty acids and eventually triglycerides, lipolysis hydrolyses triglycerides to generate free fatty acids and mono- or diacylglycerol or free glycerol. The enzyme fatty acid synthase plays a central role in animal *de novo* lipogenesis. The enzyme catalyzes the conversion of acetyl-CoA and malonyl-CoA to palmitate (a 16-carbon saturated fatty acid). This process is one of the steps involved in the synthesis of endogenous lipids in the body and may lead to the development of obesity if it becomes excessive. Polyphenols can inhibit the enzyme fatty acid synthase activity and block the lipogenic pathway *in vivo*. Bee bread polyphenols significantly reduced the obesity index by inhibiting fatty acid synthase activity in the high-fat diet-induced obese rats [53]. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase and was reported to prevent the enzyme's activity in prostate cancer cells, thereby reducing endogenous lipid synthesis [54]. Chokeberry-derived polyphenols suppressed fatty acid

synthase activity in 3T3-L1 cells, significantly decreasing body weight and serum triglyceride [55]. Additional polyphenols studied for their ability to inhibit fatty acid synthase are summarized in Supplementary Table S2. Screening for fatty acid synthase inhibitors from diverse plant polyphenols could be an important area of research in obesity treatment. Other enzymes that can be significantly involved in obesity development are alpha-amylase and alpha-glucosidase, which hydrolyze starch and carbohydrates, respectively.

5.3. Polyphenols Suppress Lipogenesis of the Adipose Tissue via Obesity-Related Transcription Factors

Obesity is often associated with several disorders, including excessive growth of white adipose tissue [26]. Adipocytes are synthesized from multipotent mesenchymal precursor cells that commit to preadipocytes and then either remain inactive or further differentiate to become mature adipocytes [56]. The process of differentiation is tightly controlled by multiple transcription factors, including miRNA and extracellular hormones such as insulin [56]. The miRNAs are short nucleotides, endogenous non-coding RNAs regulating various biological processes such as adipogenesis and fat metabolism in the body [26]. Of particular relevance, many miRNAs, including miR-335, 103, and 143, are often upregulated during adipogenesis [26,56]. Therefore, substances that can prevent the upregulation of miRNAs may substantially inhibit obesity development. An animal model experiment reported that polyphenols from green tea (especially epigallocatechin gallate) suppressed the expression of miR-335 in white adipose tissue [26]. Since miRNA is a link between weight gain and impaired metabolism in adipose tissue, the study demonstrated that the suppression of miR-335 by polyphenols significantly prevented weight gain and reversed virtually all metabolic complications induced by obesity in mouse white adipose [26]. Besides miRNA inhibition, the beneficial effects of polyphenols in suppressing lipogenesis in adipose tissue have also been linked to their effects on adenosine monophosphate (AMP)-activated protein kinase (AMPK) [57]. AMPK is an important regulator of energy balance in the body and is one of the molecular targets for drugs used to treat obesity [58]. Activation of AMPK protects against diet-induced obesity due to increased body energy expenditure resulting from the high oxygen consumption rate of white adipose tissue (the process is referred to as beiging) [58]. Thus, targeting AMPK activation in adipose tissue can offer a therapeutic strategy for managing obesity. In a study of the anti-obesity activity of green tea polyphenols, Rocha et al. reported a repression of de novo lipogenesis in adipose tissue in diet-induced obese rats, which was accompanied by AMPK activation [57]. Another research showed that gallotannin derivatives from mango suppressed adipogenesis by converting white adipocytes into beige adipocytes in 3T3-L1 adipocytes through the AMPK pathway [59]. Targeting lipogenesis by polyphenols is an effective strategy for managing obesity.

5.4. Polyphenols Modulate Thermogenesis and Mitochondrial Biogenesis

Mitochondria functions to produce energy via oxidative phosphorylation and are also involved in various cellular roles in the body, including apoptosis, calcium balance, and the production of free radicals [60]. Due to these multiple functions, mitochondrial dysfunction can directly or indirectly trigger the origin of numerous diseases, such as obesity and diabetes [60]. Previous studies have demonstrated that obesity development can be linked to decreased mitochondrial respiration, mitophagy signaling, increased production of free radicals, and apoptosis [61]. Therefore, therapeutic strategies directed toward restoring mitochondrial function are promising methods in the treatment of obesity. Peroxisome proliferator-activated receptor-gamma coactivator 1 (PGC-1) consisting of family members, PGC-1 α , PGC-1 β , and PRC (PGC-1-related coactivator) is one of the key regulators of mitochondrial functions [62]. The PGC-1 α coactivators, for instance, regulate the expression of mitochondrial transcription factor A (TFAM), which controls mitochondrial DNA replication and transcription [62]. These activities are managed through phosphorylation, methylation, and acetylation processes. Reversible acetylation of PGC-1 α regulated by sir-

tuin 1 (SIRT1) has been shown to substantially alter mitochondria's transcriptional activity, leading to various health problems, and excessive weight gain is one of them [60,62].

Recently, it has been shown that markers of mitochondrial biogenesis are upregulated in polyphenol-treated mice (Supplementary Figure S1). An *in vivo* study also revealed that resveratrol, increasing SIRT1 activity, modulated PGC-1 α functions and impacted the regulation of energy balance [63]. The study also showed that resveratrol potently induced mitochondrial activity by not only activating PGC-1 α but also increasing oxidative Type-I muscle fibers [63]. These effects triggered by resveratrol were crucial in enhancing the animals' resistance to diet-induced obesity and tolerating insulin resistance [63]. On the other hand, thermogenesis is a process in which heat is produced in the body, mainly due to basal metabolism. Most animals regulate thermal homeostasis via brown adipose tissue. Thus, brown adipose tissue has been identified as a critical site for energy expenditure in the form of thermogenesis. In low temperatures, sympathetic nerves are stimulated to activate brown adipose tissue via β 3-adrenoreceptors to facilitate thermoregulation [60]. Additionally, thermogenesis in brown adipose tissue can be stimulated by diet-induced stress, which is crucial in obesity [60]. Numerous reports have investigated how thermogenesis regulation via brown adipose tissue plays a protective role against obesity [64,65] and the potential effects of polyphenols in this process [66,67]. Vanillic acid reduces body weight gain and maintains body temperature by promoting thermogenesis and mitochondrial biogenesis of brown adipose tissue [66]. According to the report, vanillic acid-activated brown adipose tissue thermogenesis promoted inguinal white adipose tissue browning, thereby inhibiting obesity development [66]. Epigallocatechin-3-gallate feeding of mice decreased body weight gain and plasma and liver lipids [67]. According to the study, the treated mice exhibited higher body temperature and increased mtDNA content in brown adipose tissue, indicating increased thermogenesis and mitochondrial biogenesis [67]. Therefore, the research on the effects of polyphenols on thermogenesis and mitochondrial biogenesis may enhance understanding of the importance of these compounds in the body and provide hope for developing functional foods to prevent or treat obesity. Supplementary Table S3 summarizes studies on the roles of polyphenols in inducing thermogenesis and mitochondrial biogenesis.

5.5. Gut Microbiota Modulation

Human gut microbiota (GM) is a complex ecosystem. Gut microbiota performs critical roles in diet processing, eventually influencing several physiological functions in the host organism. These functions include harvesting energy from indigestible food, altering fatty acid oxidation, controlling satiety, lipogenesis, production of bile acid, and affecting innate immunity [68]. Thus, gut microbiota dysbiosis can cause the progression of various chronic conditions related to these activities. Diet represents an essential factor in regulating the symbiotic relationship of mammalian gut microbiota since it provides the energy and substrates for the life and growth of the organisms. The interaction between dietary polyphenols and gut microbiota has been well documented [68]. There is a two-way interaction between polyphenols and the gut microbe that affect human metabolism and could reduce the risk of obesity: gut microbiota enzymatically biotransforms polyphenol structure producing the metabolized forms of the compounds (discussed in Section 5), while polyphenols can potentially change gut microbiota composition by inhibiting the growth of pathogenic bacteria but enhancing the growth of beneficial microbes. Thus, gut microbiota can regulate the bioavailability of the unabsorbed polyphenols, which reciprocally modulate their functions [69].

The mechanisms through which phenolic compounds modulate the gut microbiota is a subject that requires further elucidation. The heterogeneity of the polyphenols, their food sources, their coexistence with other bioactive compounds within a regular diet, and the complexity of the human gut microbiome make it challenging to understand how polyphenols modulate the microbial composition of the human gut. However, the mechanisms may involve both direct and indirect interactions. Phenolic compounds

can simultaneously stimulate beneficial bacteria growth but inhibit pathogenic bacterial proliferation through their bactericidal or bacteriostatic effects in the gut [70]. The imbalance between *Firmicutes* and *Bacteroidetes* has been associated with obesity development and insulin resistance [70]. It has been found that a decreased ratio of *Firmicutes/Bacteroidetes* (F/B) can help prevent the development and progression of obesity [69]. In a study of catechin-rich tea infusion, a significant decrease in *Firmicutes* and increases in the number of *Bacteroidetes* and *Proteobacteria* were observed, which correlated to overall reduced body weight in a mouse model of high-fat-diet-induced obesity [69]. The role of foods in enhancing the beneficial microbes and reducing pathogenic ones at a species level is of particular importance. Feeding C57BL/6J mice with a high-fat diet supplemented with three types of tea (green tea, oolong tea, and black tea) infusions for 13 weeks was found to increase diversity and positive change in the microbial community in the gut, which consequently decreased the accumulation of adipose tissue in the mice [71]. This study revealed that phenolic acids, flavonols, and alkaloids from the three types of tea modulated the composition of gut microbiota such that *Alistipes*, *Rikenella*, and *Akkermansia* were increased, thereby preventing obesity development [71]. Additionally, one of the key species of beneficial bacteria in the gut is the mucin-degrading species of bacteria, *Akkermansia muciniphila*. Recently, *Akkermansia muciniphila* has received increasing attention because of its ability to improve body weight and protect against various features of metabolic syndrome [72]. Polyphenol-rich cranberry extract administration was found to revert an essential shift in the gut microbiota of mice by triggering an increase in the relative abundance of *Akkermansia* in high-fat/high-sucrose-fed rats [72]. Thus, plant foods rich in polyphenols can modulate microbiota composition, forming a baseline that might offer a dietary intervention strategy for obesity treatment. Supplementary Table S4 summarizes the studies on the effects of polyphenols on gut microbiota composition in obesity.

6. A Comprehensive Review of Cellular, Animal, and Human Models Investigating the Potential of Polyphenol-Rich Extracts against Obesity

6.1. Studies on the Anti-Obesity Effects of Polyphenol-Rich Extracts Performed in Cell and Animal Models

Studies on cell model: After in vitro, ex vivo studies are the second step in establishing the effects of plant phytochemicals on health. Plant extracts' in vitro anti-obesity potential is often assessed by evaluating their inhibitory activities against pancreatic lipase, alpha-glucosidase, alpha-amylase, and fatty acid synthase enzymes (discussed above). However, to understand the initial molecular mechanism undergoing obesity in ex vivo/in vitro, the cell culture model (mostly, 3T3-L1 cell line) has been used as one of the most reliable models for evaluating the cell differentiation of preadipocytes into adipocytes. Accumulation of fat and the differentiation of adipocytes are often related to obesity development. Soeng et al. found that rambutan seed extract (rich in polyphenols) decreased triglyceride levels and inhibited glucose-6-phosphate dehydrogenase (G6PDH), which promotes adipogenesis, thereby reducing obesity in ex vivo in the 3T3-L1 cell line [73]. Treatment with black soybean anthocyanins at a concentration of 12.5–50 µg/mL prevented obesity development by inhibiting the proliferation of both preconfluent preadipocytes and mature postconfluent adipocytes in 3T3-L1 cells [74]. Pinent and colleagues discovered that grape-seed-derived procyanidins treatment inhibited adipogenesis in the 3T3-L1 cell, mainly at the induction of differentiation [75]. Chokeberry polyphenols suppressed fatty acid synthase activity in 3T3-L1 cells [55]. The study found that by inhibiting the enzymes, polyphenol-rich Chokeberry significantly decreased the animal body weight and serum triglyceride [55].

Studies on animal models: The anti-obesity potential of polyphenols-rich plant extracts have not been demonstrated in vitro and ex vivo studies alone; their anti-obesity properties have also been shown in animal models as in vivo evidence. Even though the anti-obesity mechanisms of action depend on the extract and the animal model used, studies agree on general anti-obesity events that occur with polyphenol intake. Most studies report the reduction of animal body weight, fat tissue size, and downregulation of pro-obesity markers when animals such as mice are fed a mixture of polyphenol-rich extract and a

high-fat diet. Furthermore, there is agreement that the intake of polyphenol-rich extracts improves serum triglycerides and reduces total cholesterol and LDL-cholesterol in plasma. Cellular and animal studies on the potential effects of polyphenol-rich extracts on obesity were summarized in Table 3.

Table 3. Cellular and animal studies on the potential effects of polyphenols and polyphenol-rich extracts on obesity.

Polyphenol	Model	Treatment Dose	Key Observation	References
Polyphenols-rich blueberry extract	Mice	Mice were provided with 15.6 mg/kg BW per day for 12 days	Inhibited body weight gain and reverted lipid metabolism to normal. Decreased triglyceride levels.	[76]
Rambutan seeds extract (containing alkaloid, terpenoid, triterpenoid, and flavonoids)	3T3-L1 cell line	Cells were treated with varying concentrations of the extracts (10 and 50 µg/mL)	Inhibited glucose-6-phosphate dehydrogenase (G6PDH) which promote adipogenesis. Reduced by 32% triglyceride content in cells treated at day zero. Downregulated genes responsible for preadipocyte differentiation but elevated preadipocyte factor-1 (Pref-1).	[73]
Procyanidin-rich grape seed extract (GSPE)	3T3-L1	Cells were treated with 140 mg/L GSPE (dissolved in water) for 24 hr on days 0, 2, or 4.	Elevated energy expenditure and brown adipose tissue thermogenesis.	[75]
Polyphenol-rich cranberry extracts	Mice	Mice were provided with 0.75% (w/w) of polyphenol-cranberry-rich extract per day for 16 weeks.	Decreased body weight and fat mass. Increased expression of insulin receptor β and insulin-induced phosphorylation of PKB in skeletal muscle, white adipose tissue (WAT), and brown adipose tissue (BAT), thereby inducing thermogenesis.	[77]
Polyphenol-rich totum-63 extract	Mice	Mice were fed with a high-fat diet for 12 weeks, followed by supplementation with Totum-63 (2.7% w/w) for 4 weeks.	Inhibited obesity-induced inflammation and oxidative stress	[78]
Polyphenol-rich extracts from <i>Antirhea borbonica</i> , <i>Doratoxylon apetalum</i> and <i>Gouania mauritiana</i>	3T3-L1	Cells were treated with polyphenol-rich from the respective extract (0–200 µM GAE) for 24, 48, and 72 h	High doses of 200 mg/kg reduced body weight by 19.4%, while 50 and 100 mg/kg doses did not significantly affect body weight.	[79]
Anthocyanin-rich blueberry extract	Mice.	Mice were fed with 50–200 mg/kg per day for 8 weeks	Reduced overall body weight	[80]
Cyanidin 3-O-β-D-glucoside (C3G)-rich blackberries	Rats	Rats were given 10% (w/w) of C3G-rich blackberry	Decreased body weight and also elevated the mRNA expression of energy expenditure-related genes	[81]
Acacia-rich polyphenols (containing catechin-like flavan-3-ols, such as robinetinidol and fisetinidol)	Mice	Mice were provided with a high-fat diet supplemented with 2.5–5.0% (w/w) of acacia polyphenol extract for 7 weeks.	Inhibited the proliferation of both preconfluent preadipocytes and mature postconfluent adipocytes	[82]
Anthocyanins-rich black soybean extract	3T3-L1 cells	Cells were treated with anthocyanins-rich black soybean extract (at a concentration of 12.5–50 µg/mL)		[74]

BW, body weight; IL-6, Interleukin 6; TNF, tumor necrosis factor-alpha; AMPK: adenosine monophosphate-activated protein kinase; (iWAT/eWAT, inguinal/epididymal white adipose tissue; PKB, protein kinase B.

6.2. Studies on the Anti-Obesity Effect of Polyphenol-Rich Plant Extracts Performed in Humans

The impact of polyphenols supplementation should be tested on human subjects before consumption. The US Food and Drug Administration only considers human clinical trials as strong evidence about a health claim of a bioactive compound. Despite the increased research on polyphenols as anti-obesity agents, only a few clinical trials have effectively evaluated the efficacy of these compounds on obesity. A number of polyphenol-rich plant extracts have been investigated for their ability to reduce obesity development in human clinical trials. Grape, orange, and citrus fruits are increasingly being investigated for their anti-obesity effects. Despite most studies being carried out in vitro and in vivo, some clinical trials have reported grape, orange, and citrus fruits as anti-obesity effects. Dallas et al. described a significant improvement in obesity parameters when a commercial drink

consisting of a mixture of polyphenol-rich citrus extract, orange, grapefruit, sweet orange, and guarana was investigated for their anti-obesity effects [83]. The 95 obese participants who consumed two capsules of citrus polyphenol extract containing orange, grapefruit, sweet orange, and guarana for 12 weeks had reduced body weight and abdominal fat [83]. The summary of the anti-obesity effects of polyphenol-rich extracts has been summarized in Table 4.

Table 4. Anti-obesity effects of polyphenol-rich extracts in clinical trials.

Polyphenol	Subject	Country	Study Objective	Intervention	Key Observations	References
Polyphenol-rich green tea extract	N = 100, Women, age: 16–60 years BMI: >27 kg/m ²	Taiwan	To examine the effect of green tea extract on obesity.	The subjects consumed green tea containing (491 mg of catechins containing 302 mg EGCG per day) for 12 weeks.	0.3% reduction in body weight (Equiv. 0.15 kg) after 12 weeks of treatment. Significantly reduced triglyceride levels.	[84]
Polyphenol-rich chocolate (contained mainly epicatechin)	N = 1017, Men and women aged: 20 to 85 years	USA	To evaluate the effect of chocolate rich in phenolic compounds on body mass index.	Subjects ate chocolate, with a mean intake of 2.0 (2.5) times/week and exercised 3.6 (3.0) times/week.	Improved BMI.	[85]
Yerba Mate (<i>Ilex Paraguariensis</i>) (rich in (quercetin rutin, chlorogenic and caffeic acids)	N = 15 BMI < 35 and ≥ 25 kg/m ² and waist-hip ratio (WHR) ≥ 0.90 for men or ≥ 0.85 for women N = 100, postmenopausal women age: 50–70 years BMI 28–40 kg/m ²	Korea	To investigate the efficacy of Yerba Mate supplementation against obesity.	The subjects were given 13 g/day of Yerba Mate capsules for 12 weeks.	Decreased BMI (<i>p</i> = 0.036), body mass fat (<i>p</i> = 0.030), and waist-hip ratio (<i>p</i> = 0.004).	[86]
Soya isoflavones	N = 100, postmenopausal women age: 50–70 years BMI 28–40 kg/m ²	Canada	To assess the combined effect of exercise and soy isoflavones on obesity.	Subjects consumed a 70 mg/day dose of isoflavones for 12 months.	Decreased trunk fat mass and increased lean body mass.	[87]
Mixture of polyphenols	N = 573, 277 men, 296 women, age: 66.2–68.3 years BMI > 30 kg/m ²	Spain	To assess the associations between total polyphenol and obesity parameters among the elderly after a long period of polyphenol intake (measured by overall urinary polyphenol level).	Participants known to consume foods rich in polyphenols were recruited and followed up for 5 years. Spot urine samples were collected and analyzed for total polyphenols, and obesity indicators were measured.	Increased consumption of dietary polyphenols was associated with improved BMI after 5 years of consumption.	[88]
Citrus polyphenolic extract of red-orange, grapefruit, and orange (Sinetrol-XPur)	N = 95, 55 women and 40 men, age: 22–45 years BMI 26–29.9 kg/m ²	France	To investigate appropriate polyphenolic-rich combinations that would help reduce body fat, inflammation, and oxidative stress in overweight subjects.	Subjects consumed two capsules of citrus polyphenolic extract containing orange, grapefruit, sweet orange, and guarana daily for 12 weeks.	Reduced abdominal fat and overall body weight.	[83]
Polyphenol-rich green tea extract	N = 35, Men and women, mean, age 42.5 ± 1.7 years BMI: 36.1 ± 1.3 kg/m ²	USA	To compare the effects of green tea polyphenols with controls on body weight and safety parameters in obese subjects.	Subjects took either four cups of decaffeinated green tea beverage or two capsules of green tea extract containing either 28 mg or 870 mg of catechins (GC, GCG, EC, ECG, EGC, and EGCG) daily for 8 weeks.	Decreased body weight. Improved LDL-cholesterol level	[89]
Licorice flavonoid oil	N = 22, men and women, age: 20–53 years BMI: 25.0–36.0 kg/m ²	USA	To investigate the effect of licorice flavonoid oil supplementation on obesity-related health markers.	Subjects consumed three capsules of licorice flavonoid oil, 300 mg per day for 8 weeks.	Inhibited the total cholesterol level. Decreased total triglycerides.	[90]

LDL, low-density lipoprotein; HDL, high-density lipoprotein, LFO, licorice flavonoid oil; BMI, body mass index; GC, gallic catechin; GCG, gallic catechin-3-gallate; EC, epicatechin; ECG, epicatechin-3-gallate; EGC, epigallocatechin; EGCG, epigallocatechin-3-gallate.

6.3. Anti-Obesity Effects of Commonly Studied Polyphenols-Rich Foods

Recently, research has highlighted the bioactive roles of polyphenols against obesity. Numerous foods, consisting of grains, fruits and vegetables, have been studied for their anti-obesity effects. However, current research has paid particular attention to food materials known to contain a certain amount of polyphenols, enough to exert anti-obesogenic effects when consumed. The attention has been put particularly on green tea, berry fruits, citrus fruits, coffee, cocoa, and ginger polyphenols, with an effort to advance their extraction, characterization, and understanding of their health benefits (Figure 4).




Figure 4. Major Polyphenols responsible for anti-obesity effects in green tea, cocoa, coffee, berry, citrus fruits, and ginger.

Green tea polyphenols: Green tea is one of the most popular worldwide beverages. Green tea extract contains diverse polyphenolic contents and is particularly abundant in catechins with various health effects. Polyphenol-rich green tea extract is one of the most studied for its health activities. Catechins are the most abundant polyphenols with known biological activities in tea. Catechins are present from 15%–20% by weight in green tea. Epigallocatechin gallate (EGCG), a kind of catechin, exerts an inhibitory effect on acetyl-CoA carboxylase, thereby preventing obesity development [91]. Polyphenol-rich green tea extracts have been widely studied for their anti-obesity effects. The potential mechanism of how green tea catechin induces anti-obesity effects involves changes in fatty acid oxidation and metabolism. For example, under the influence of the sympathetic nerve, norepinephrine (NE) stimulates lipolysis in peripheral tissues, including adipose, liver, and skeletal muscle, releasing free fatty acids into circulation while at the same time up-regulating hepatic lipid metabolism [92]. Studies in rodents have shown that green tea polyphenols could prevent obesity by stimulating lipolysis in peripheral tissues (adipose, liver, and skeletal muscle), releasing a free hypothesis [93,94]. Randomized, controlled intervention trials have also confirmed that consuming tea rich in polyphenols exerts beneficial effects against obesity via these mechanisms [95]. However, the anti-obesity effects of green tea polyphenols is described as a cumulative process that occurs over time

in humans [92]. Auvichayapat et al. evaluated the effects of green tea catechin (GTC) ingestion (141 mg GTC + 87 mg caffeine) as part of a weight loss program among Thai men and women [96]. During the 8th and 12th weeks of the study period, Auvichayapat et al. reported that loss in body weight was significantly increased by supplementation. A 183.38 kJ/day difference in resting energy expenditure was observed, while the difference was 0.02 for the respiratory quotient. Thus, the researchers concluded that green tea could reduce body weight by enhancing energy expenditure and increasing fat oxidation [96].

Berry fruit polyphenols: In recent years, demand for fresh berry fruits and berry products has dramatically increased, which largely fuels the cultivation and production of berry fruits. Raspberries, blueberries, mulberries, lingonberries, blackberries, black chokeberries, elderberries, cranberries, and strawberries are vast reservoirs of polyphenols and other bioactive metabolites. Their anti-obesity potentials remain significantly attractive. Jiang and colleagues comprehensively reviewed the effects of berry fruits as anti-obesity foods [97]. Polyphenols, including anthocyanins (mainly glycerides of cyanidin, delphinidin, petunidin and malvidin), flavonols (rutin and quercetin), phenolic acids, and procyanidins have been identified in berries [97]. From the perspective of actual clinical experiments, the anti-obesity of freeze-dried blueberry powder was performed on 32 men and women with BMI between 32 and 45 kg/m² [98]. The study subjects consumed 22.5 g of blueberry powder twice daily for 6 weeks; the supplement contained 32.49 mg/g of total phenolics; 14.84 mg/g of anthocyanins. The supplementation improved body weight and insulin sensitivity at the end of the study period [98]. A mixture of cranberry and strawberry polyphenol extracts was evaluated for the ability to reduce obesity among 116 subjects (BMI ≥ 25 kg/m²) [99]. The extracts contained 20.04 mg/120 mL of proanthocyanidins and 28.206 mg/120 mL of phenolic acids, and the subject consumed 120 mL of beverage daily for 6 weeks. The supplementation improved insulin sensitivity and other obesity parameters [99]. Moreover, 38 subjects (22 women and 16 men) consumed 45 g lyophilized berries 100 mg extract thrice daily for 2 months [100]. The supplement consisted of 60 mg/100 mg of total polyphenols, with 20 mg/100 mg of anthocyanins (cyanidin 3-galactoside (64.5%) and cyanidin 3-arabinoside (28.9%). The supplement was able to restore to improve tested parameters [100]. The anti-obesity mechanism of berry fruits may be due to the regulation of lipid metabolism, including suppressing lipogenesis and improving fatty acid oxidation. Additionally, the ingestion of berry fruits such as mulberry has also been reported to prevent obesity by enhancing the growth of beneficial gut microbes [101].

Citrus polyphenols: Polyphenols from citrus have been evaluated as one of the attempts to prevent and treat obesity. Experimental results are not entirely consistent; however, most of the published papers attribute the anti-obesity effects of citrus polyphenols to their impact in reducing adipose tissue, increasing biochemical reactions related to fat oxidation as well as improving the serum lipid profile. Citrus fruits, consisting mainly of flavonoids as the primary polyphenols, are the most studied citrus products [102]. Among the flavonoids in citrus are flavanones, flavones, flavonols, and anthocyanins. Hesperidin, narirutin, naringin, and eriocitrin are the most known flavanones in citrus fruits [102]. Other phenolic compounds, including p-coumaric, ferulic, caffeic and sinapic acids, can also be found in these foods in significant amounts. Although not often studied for their health effects, bitter orange is a good source of flavonoids that could exert anti-obesity effects. Eight-week-administration of bitter orange (*Citrus aurantium* Linné) in high-fat diet-induced obese mice resulted in a significant decrease in body weight, adipose tissue weight and serum cholesterol [103]. Moreover, in further in vitro study, sinetrol (citrus-based polyphenolic dietary supplement) inhibited cAMP-phosphodiesterase in cell models and human clinical studies [104], whereas lemon peel polyphenols enhanced peroxisomal β -oxidation through up-regulation of mRNA levels of PPAR α and acyl-CoA oxidase in in-vivo mice model study [105]. Thus, regulation of lipid metabolism, energy expenditure and adipogenesis has been described as significant mechanisms of anti-obesity effects by citrus polyphenol extracts.

Coffee and cocoa polyphenols: Cocoa comprises over 380 known bioactive components, 10 of which are considered psychoactive compounds. In their original form, cocoa beans are inedible due to their high concentration of polyphenols, which often contribute to the unfavorable bitter flavor [106]. However, processed cocoa products, such as chocolate, contain reduced total polyphenolic content, a decrease from 100% to about 10% in levels [106]. Three groups of polyphenols, namely catechins, anthocyanidins, and proanthocyanidins, are known to be the dominant compounds in cocoa. Of the total polyphenols, catechins constitute 37%, anthocyanidins comprise 4%, and proanthocyanidins about 58%. (–)-epicatechin is the most abundant, constituting 35% of the total catechins in cocoa beans, while (+)-catechin, (+)-gallocatechin, and (–)-epigallocatechin are only present in trace amounts [107]. Cocoa beans and cocoa-based products have been consumed over decades. Attempts have been made to evaluate the anti-obesity effect of cocoa beans and other cocoa-derived products in the past years. Golomb et al. conducted a cross-sectional study to investigate the impact of chocolate (cocoa-based product) intake on the body weight of 1018 subjects [85]. The researchers noted that chocolate consumption decreased the subjects' BMI and overall body weight [85]. Ferrazzano et al. [108] discovered that mice fed with a cocoa-enriched diet had reduced body weight, mostly due to decreased adipose tissue synthesis. The researchers concluded that the polyphenols contained in cocoa might have significantly contributed to anti-obesity effects by decreasing fat synthesis. Cocoa and chocolate consumption may also have beneficial effects on satiety, which may help prevent weight gain [107].

On the other hand, coffee is the second most consumed beverage in the world, after tea. Its health benefits have been largely associated with its main component, caffeine. However, coffee contains many other bioactive compounds, approximately 2000 different chemicals. The primary polyphenols in coffee are chlorogenic acid and its derivatives, which account for 3% *w/w* of the roasted coffee powder. A single cup of coffee is estimated to contain 20–675 mg of chlorogenic acid. The anti-obesity effect of coffee has been studied, especially for at least 10 years. The findings have shown that coffee polyphenols are effective anti-obesity agents. For example, 44 patients with non-alcoholic fatty liver disease were enrolled in a double-blind, placebo-controlled clinical trial and then administered green coffee bean extract (1 g/day) for 8 weeks [109]. Supplementation with green coffee bean extract improved the levels of triglyceride, total cholesterol, free fatty acids, and fasting blood sugar [109]. A study conducted among 93,179 individuals showed that coffee intake of up to four cups/day lowered the risk of obesity with an odds ratio (ORs) of 0.82–0.86, compared with non-coffee drinkers [110]; however, this study failed to specify metabolites which were responsible for the observed effects.

Ginger polyphenols: Ginger (*Zingiber officinale*) is a popular spice and vegetable used as a traditional medicine in many countries to treat various diseases. It has three primary phenolic compounds, namely: gingerols, zingerone, and shogaols. Gingerols contribute to the pungent taste of ginger. The beneficial effect of ginger on obesity prevention and treatment has been recently considered, and some promising results from experimental animals have been published [111,112]. It is reported that polyphenols in ginger could influence many vital parameters of obesity through mechanisms such as stimulating enhanced thermogenesis and energy expenditure, suppressing appetite, stimulating lipolysis, and inhibiting intestinal absorption of dietary fat [112,113]. However, most of these results are preliminaries since they have yet to be confirmed in clinical trials. Ginger extracts suppressed the expression of genes related to adipogenesis γ (PPAR- γ) and adipocytes in an animal model [112]. When obese rats were fed with ginger extracts, serum metabolites were significantly restored, and glucose tolerance was improved [112]. In a clinical trial, a randomized, double-blind, placebo-controlled was performed using steamed ginger ethanolic extract (SGE) containing a high 6-shogaol content [114]. Following the supplementation period, mean body weight, body mass index, and body fat level were significantly lower in the SGE group than in the placebo group [114], confirming polyphenol-rich ginger extract as anti-obesity agents.

Olive polyphenols: Recently, among the most known polyphenols sources are olive products. The high polyphenol content in these products has aroused growing interest, and studies have been carried out to determine their potential therapeutic ability. For olive oil, the most studied olive product, the major polyphenols associated with its health benefits include oleuropein aglycone, hydroxytyrosol, oleacein, and oleocanthal [115]. Therefore, the health functions and sensory attributes of olive oil depend not only on the content of free fatty acids but also on its levels of polyphenols. Indeed, polyphenols are responsible for the taste of olives. Nonetheless, factors such as cultivar, environmental conditions, cultivation practices, and fruit ripening stage affect the levels of polyphenols in olive oil [115]. Polyphenols derived from olive oil have been reported to modulate obesity. A clinical study involving the intake of 330 mL of olive oil leaf tea 3 times daily during mealtime for 12 weeks demonstrated the efficacy of olive leaf against obesity development [116]. After the intervention, serum triglycerides and low-density lipoprotein cholesterol levels decreased significantly in the oil-leaf tea-treated group ($n = 28$). Thus, olive products have been found to have lipid-lowering effects.

7. Bioavailability of Polyphenols, Metabolism by Gut Microbes, Post Absorption Fate, and Eventual Effect on Obesity

For polyphenols to exert health benefits, they must be absorbed by the human body. Most polyphenols are absorbed through an active transport mechanism that depends on the presence of sodium-dependent glucose transporter 1 (SLGT1), a protein entrenched along the epithelium cell walls [117]. Once absorbed, polyphenols and their metabolites reach tissues and influence the activities of a target tissue/organs related to a disease, thereby improving health. However, the ability of phenolic compounds to be absorbed into the body depends on their bioavailability, which is affected by several factors. The bioavailability of polyphenols can be influenced by the presence of other food components, such as lipids, carbohydrates and proteins when consumed simultaneously [117,118]. For instance, a clinical trial in humans demonstrated that the bioavailability of chlorogenic acids derived from coffee could be reduced by a matrix consisting of coffee and milk (when coffee and milk are consumed simultaneously [119]. In contrast, some food matrices, such as natural almond skin, can enhance the accessibility of polyphenols, while polyphenol-rich cinnamon extract can be incorporated into defatted soy flour containing high protein to improve polyphenol bioavailability [118]. In addition to the effects from the surrounding food components, the hydrophobicity of polyphenols can also significantly affect their absorption along the gut. Hydrophobic polyphenols have relatively low solubility in water, gastric fluids, and small intestine fluids; they often precipitate in these fluids, reducing the amount available for absorption [117]. Moreover, the presence of gut microbial enzymes that hydrolyze phenolic compounds into more minor metabolites significantly affects their bioavailability [117].

Polyphenol metabolism along the gut involves a series of stages. It is believed that phenolic compounds derived from diets are frequently conjugated as glycosides, which change to aglycones when metabolized by gut microbiota [68]. The gut microbiota hydrolyses these polyphenol glycosides and esters, reduces their nonaromatic alkenes, and cleaves their overall skeletons [68]. The result is the generation of less complex products, such as phenolic acids and hydroxycinnamates. Only 5–10% of polyphenols can be directly absorbed in the small intestine, while the remaining (90–95%) reach the colon, where microbial enzymes degrade them before their absorption [68,69]. Some of the bacteria related to the degradation of polyphenols include *Lactobacillus spp.*, *Enterococcus casseliflavus*, *Flavonifractor plautii*, *Slackia equolifaciens*, *Eubacterium ramulus*, *Eggerthella lenta*, and *Bifidobacterium spp.* [25]. *Eubacterium* metabolizes flavonoids, while *Bifidobacterium* and *Lactobacillus* species are involved in releasing hydroxycinnamic acids from the parent compound in the colon [25]. Meanwhile, *Bacteroidetes* and *Firmicutes* are the major groups involved in the colonic metabolism of undigested food remnants, including unabsorbed polyphenols [69]. The gut microbiota contains large quantities of various enzymes that modify food compo-

nents before they are used in the body or released as waste. Enzymes such as glycosidases, amidases, and esterases catalyze various reactions, including decarboxylation, oxidation, reduction, demethylation, isomerization, and ring cleavage, leading to the production of several types of catabolites of dietary polyphenols [120]. In the mouth, the mastication process takes place; polyphenols interact with digestive enzymes, which destroy their structure as digestion begins. In the stomach, the compounds are released from the food matrix, and the polymeric polyphenols and their glycosidic bond are hydrolyzed by acids [121]. However, most of the polyphenol glycosides resist acid hydrolysis in the stomach and reach the small intestine intact. Once they arrive in the small intestine, enzymatic deglycosylation of polyphenols and absorption of about 5–10% polyphenols take place [121].

Absorbed polyphenol products, through the bloodstream, rapidly reach the liver, where they are further hydrolyzed by phase II metabolism before they are eventually excreted outside the body via urine. At the same time, the unabsorbed polyphenols, mostly flavonoids linked to a rhamnose moiety, organic acids, lipids, and polymers, and those bound to dietary fiber and protein, as well as hydroxycinnamic acids esterified to sugars, reach the colon for further digestion; they cannot be directly absorbed in the small intestine. In the colon, gut microbiota hydrolyses the unabsorbed polyphenols to give rise to small phenolic acids and aromatic catabolites [120,121]. These polyphenol by-products are absorbed into the blood and arrive in the liver, where they are further metabolized before being released in urine; however, some of the unabsorbed metabolites from the parent polyphenols are eliminated via feces [120,121]. Figure 5 offers a detailed summary of the polyphenol metabolic process along the human gut.




Figure 5. Metabolism fate of polyphenols by the human gut microbiota. In the mouth, the structure of polyphenols is broken down by enzymes, releasing the compounds from the food matrix. In the stomach, the polymeric polyphenols and their glycosidic bonds are hydrolyzed as the digestion process continues. Once they reach the small intestine, polyphenols undergo enzymatic deglycosylation, and absorption of some digested compounds (5–10%) takes place. The absorbed phenolic compounds enter the circulation and reach the liver, where they are metabolized further into smaller metabolites. At the same time, in the large intestine, gut microbiota hydrolyses unabsorbed polyphenols, making them available for absorption into the blood stream. Eventually, polyphenols metabolites are released from the body either through fecal matter or urine excretion.

There is a huge body of literature evidence reporting on the biological functions of polyphenol metabolites generated by gut microbiota-mediated biotransformation [25]. The microbial enzymes may eliminate glycosides, glucuronides, and sulfates from unabsorbed polyphenols producing aglycons, which are further digested into ring-fission products depending on the type of polyphenol involved. Flavonols such as quercetin-3-O-glucoside are hydrolyzed into their metabolite-derivative products by gut microbiota at their A and B rings. *Enterococcus casseliflavus* hydrolyses sugar moieties of quercetin-3-O-glucoside to release the aglycone quercetin and products such as lactate, acetate, and ethanol [25]. In contrast, *Eubacterium ramulus* and *Clostridium* strains metabolize quercetin, forming short-chain fatty acids (acetate, propionate, and butyrate) and other products [25]. Short-chain fatty acids are crucial metabolites in reducing obesity. The anti-obesity benefits associated with short-chain fatty acids have been reported (Table 5).

Table 5. Studies elucidating the anti-obesity effects of short-chain fatty acids (SCFA) in animal and human models.

Model	Experimental Procedure	Observation	References
Mice	Mice were fed with a high-fat diet supplemented with sodium acetate, sodium propionate, sodium butyrate or their mixture (ratio at 3:1:1)	Caused changes in the bacterial community: reduced the proportion of <i>Firmicutes</i> and increased <i>Bacteroidetes</i> .	[122]
Human	Participants received a daily dietary supplement of 24 g inulin (source of SCFA) for two investigation days, with at least 5 days of washout	Improved β -cell function with increased insulin secretion. No effects on plasma triglycerides, or free glycerol.	[123]
Mice	The mice were fed diets containing sodium acetate, sodium propionate or sodium butyrate at 5% (<i>w/w</i>).	Induced reduction in body weight and stimulated insulin sensitivity.	[124]
Mice	Animals were fed a high-fat diet supplemented with 5% acetate or propionate (in the presence of 5% cellulose).	SCFA lowered hepatic triglycerides and improved insulin sensitivity.	[125]
Human	Participants (<i>n</i> = 441) were recruited and examined for their fecal SCFA, and related markers of obesity were analyzed.	Higher SCFA in fecal excretion was associated with gut modulation effects.	[126]

The bacteria, *Clostridium coccoides*, *Bifidobacterium* spp., *Eggerthella lenta*, *Adlercreutzia equolifaciens*, *Slackia equolifaciens*, and *Flavonifractor plautii* through hydrolysis of ester bonds, carbon-ring cleavage, or dihydroxylation metabolizes **flavonols** and **proanthocyanidins** into various forms of phenolic acids [25]. The degradation pathway of **flavanones** is

similar to flavonols. The first step in the hydrolysis of naringin, a flavanone, involves a deglycosylation reaction which produces a naringenin [22]. The naringenin is biotransformed into phloroglucinol and 3-(3,4-dihydroxyphenyl) propionic acid via the cleavage of the C-ring [22]. The Isoflavone group is biotransformed into their aglycones by β -glucosidase released by gut microbiota. The aglycones can either be absorbed completely or further hydrolyzed into their metabolite forms; for example, daidzein can be converted to *O*-demethylangolensin (*O*-DMA) and equol; genistein into *p*-ethylphenol and 4-hydroxyphenyl-2-propionic acid [22]. **Flavanols** are hydrolyzed into several *O*-sulfated, *O*-glucuronidated, and *O*-methylated forms by gut microbiota. Epigallocatechin gallate, a flavanol, is biotransformed by *Eubacterium* sp. strain into 1-(3',5'-dihydroxyphenyl)-3-(2'',4'',6''-trihydroxyphenyl)propan-2-ol [127]. It is reported that **phenolic acids** such as ferulic acid can be bound to each other through linkages (8-*O*-4- or 5-5-linkages), forming dimers [22]. The gut microbes hydrolyze the 8-*O*-4 into monomeric ferulic acid, which is eventually biotransformed into 3-(3',4'-dihydroxyphenyl) propionic acid, 3',4'-dihydroxyphenyl acetic acid, 3-phenylpropionic acid, and benzoic acid [22]. Finally, as already been mentioned earlier in this article, **stilbenes** such as resveratrol trans-resveratrol are metabolized by gut microbiota, forming dihydroresveratrol, 3,4'-dihydroxy-trans-stilbene, and 3,4'-dihydroxybibenzyl.

The smaller forms of polyphenols are believed to reflect precisely the physiological effects of their parent compounds [120]. The microbiota-gut-brain axis is considered a neuroendocrine system that plays a vital role in activities controlled by the central nervous system [128]. In addition to modulating gut bacterial composition, the polyphenol metabolites can modulate brain biochemistry or directly act as neurotransmitters through the microbiota-gut-brain axis, thereby affecting body physiological activities of the brain, including those related to stress response, appetite, inflammatory injury, and obesity [128]. Figure 6 is a description of various structures of polyphenols and their metabolic products.




Figure 6. Flavonoids and nonflavonoid-type phenolic compounds that are metabolized by the gut bacteria. (A) C-ring cleavage of flavonoids. (B) Nonflavonoid-type phenolic compounds metabolized by the gut bacteria. Reproduced from Ozdal et al. [22]. Last accessed on 2 July 2022.

In their metabolized forms, the bioavailability of polyphenols is improved, and they can effectively reach the target site of the disease and exert health benefits. In fact, the anti-obesity ability of most polyphenols is based on the properties of their end product of metabolism. Thus, most of the products of polyphenol metabolism by gut microbial

have been reported to possess anti-obesity effects. Products from epicatechin metabolism such as 1,3,5-Trimethoxybenzene have been shown to inhibit adipocyte differentiation, while dihydroxyphenylpropionic acid and 3,4-dihydroxybenzoic acid, metabolic products of flavan-3-ols possess pancreatic inhibitory effects (see Table 6).

Table 6. Metabolites from the digestion of polyphenols by intestinal microbiota and their reported anti-obesity effects.

Polyphenol	Gut Bacteria Involved	Model	Main Metabolite	Major Observation	References
Epicatechin	<i>Eubacterium sp.</i> , <i>Bifidobacterium sp.</i> , <i>Lactobacillus, anaerobic cocci, and, Fusobacterium spp.</i>	In vitro study (human feces)	5-(3,4-dihydroxyphenyl)- γ -valeric acid,3-(3-hydroxyphenyl)propionic acid,4-hydroxyphenyl acetic acid	-	[129]
Quercetin	<i>Eubacterium ramulus</i> , <i>Eggerthella sp.</i>	Animal study (urine)	4-ethylphenol, Benzoic acid,4-ethylbenzoic acid	Inhibitory effects on α -amylase enzyme	[130]
Epicatechin	-	Animal study (urine)	1,3,5-Trimethoxybenzene	Inhibit adipocyte differentiation	[130,131]
Quercetin	<i>Bacteroides</i>	In vitro study (humans feces)	Hydroxyphenylacetic acid derivatives	Gut microbiota modulation	[132]
Rutin	<i>Bacteroides</i>	In vitro study (humans feces)	3,4-dihydroxyphenylacetic acid	Gut microbiota modulation	[132]
Isoflavone	<i>Streptococcus intermedius</i> , <i>Bifidobacterium spp.</i> , <i>Bacteroides ovatus</i> , <i>Streptococcus intermedius</i> , <i>Escherichia coli</i>	In vitro study (human urine)	Dihydrodaidzein (DHD), tetrahydrodaidzein (THD), equol, and O-DMA	-	[25]
Flavan-3-ols	<i>Clostridium coccooides</i> , <i>Bifidobacterium spp.</i>	In vitro study (human feces)	Dihydroxyphenylpropionic (dihydrocaffeic) acid and 3,4-dihydroxybenzoic (protocatechuic) acid (PCA)	Inhibit pancreatic lipase activities	[25,133]
Genistin,	No specific bacteria reported	In vitro study (human and animal feces)	4-hydroxyphenyl-2-propionic acid and 1,3,5-trihydroxybenzene	-	[134]
Anthocyanin	<i>Lactobacillus spp.</i>	In vitro study (human feces)	Gallic acid, syringic acid and p-coumaric acid	Inhibition of preadipocytes growth	[135,136]
Ellagic acid	<i>Gordonibacter urolithinfaciens</i>	In vitro study (human feces)	Urolithins	Inducing thermogenesis in brown adipose tissue (BAT) and inducing browning of white adipose tissue (WAT). Inducing thermogenesis in brown adipose tissue (BAT) and inducing browning of white adipose tissue (WAT)	[137,138]
Ellagitannins	<i>Gordonibacter urolithinfaciens</i>	In vitro study (human feces)	Urolithins	Inducing thermogenesis in brown adipose tissue (BAT) and inducing browning of white adipose tissue (WAT)	[139]
Naringenin	No specific bacteria reported	In vitro study (rat feces)	Phenylacetic acid, protocatechuic acid	-	[140]
Chlorogenic acid	No specific bacteria reported	In vitro study (human feces)	3-(3-hydroxyphenyl)-propionic acid	-	[141]
Resveratrol	<i>Slackia equolifaciens</i> , <i>Adlercreutzia equolifaciens</i>	In vivo and in vitro (human feces)	Dihydroresveratrol, and lunularin	-	[25,142]
Baicalin	No specific bacteria reported	In vitro study (human feces)	Baicalin and oroxylin A	Enhances pAKT, PGC-1 α and UCP1	[143,144]
Apigenin	No specific bacteria reported	Animal study (urine)	P-hydroxyphenyl acetic acid, P-hydroxycinnamic acid, P-hydroxybenzoic acid	Inhibition of adipogenesis	[145,146]

8. Improving the Bioavailability and Delivery of Polyphenols in the Body

The bioavailability of most phenolic compounds is closely related to their chemical structure. Most polyphenols exist as esters, glycosides or polymers, which are not readily available in the body in this native form. Gut intestinal transformations of polyphenols produce bioavailable and active phenolic metabolites that can easily be absorbed into the body. In their metabolized condition, these compounds can reach tissues and the brain, where they exert various biological effects. However, it is essential to emphasize that the low bioavailability of polyphenols is one of the critical drawbacks in their utilization as

functional ingredients to improve health. It is recognized that microbes in the gut are the main metabolizers of insoluble and unabsorbed polyphenols. However, it is also perceived that gut bacteria may not freely circulate along the gastrointestinal tract (GIT) without encountering harsh environments that may kill them [147]. Hence, the degradation of polyphenols may not be entirely possible in all regions of the GIT, further complicating their bioavailability. Thus, to overcome this challenge, there have been proposals to safely deliver readily-available plant active ingredients into the body using methods exploiting physiological changes in the GIT, such as osmotic control, to improve the functions of these compounds [147].

Overall different strategies can be employed to enhance the bioavailability of bioactive compounds: (i) nano-delivery systems, which demonstrate potential for the protection of these compounds during food processing or digestion process; (ii) absorption enhancer materials which facilitate bioactive compounds' membrane permeation; and (iii) excipient foods with the ability to improve nutraceuticals' biological activity [148]. Several micro- and nano-encapsulation systems have been proposed to deliver individual polyphenols or their mixtures to enhance their solubility, instability, and poor permeability in the body. Nevertheless, overall knowledge of this technology needs to be improved. The properties of micro- and nanoparticles, including their shape, surface, and stability, are thought to strongly affect active compounds' in vitro and in vivo fate to improve functionality [147]. In the literature, polyphenols-microencapsulation has been applied to enhance the bioavailability of polyphenolic compounds (Supplementary Table S5). Flavonoids are anti-obesity agents with therapeutic ability based on oral absorption and the properties of their end product of metabolism. However, most flavonoids have a low dissolution rate from solid oral forms and cleavage in the gut lumen. Thus, a diverse range of cellulose derivatives with gastro-resistant swelling effects and controlled release properties, such as cross-linked carboxymethylcellulose and cellulose acetate trimellitate, have been used to improve their functionality to deliver flavonoids in vivo and in vitro extract [149]. Microencapsulation technology has also been used in processed foods to deliver cocoa hull polyphenols into bakery products [150] and green tea polyphenols in functional bread [32]. Figure 7 describes the proposed encapsulation process of polyphenols.




Figure 7. Proposed encapsulation process of polyphenols.

Recent developments in the design of bio-based delivery systems have also led to the use of emulsions, liposomes, and hydrogels to improve the delivery and bioavailability of

polyphenols in the body. Emulsions are thermodynamically unstable colloidal dispersions typically assembled from two or more immiscible fluids. Nowadays, emulsions can be utilized to encapsulate polyphenols to enhance their bioavailability; oil-in-water is the most commonly used emulsion to encapsulate polyphenols such as quercetin [117]. Quercetin has been incorporated into perilla oil-in-water emulsions as a black bean protein-quercetin complex that acts as an emulsifier [117]. Polyphenols such as curcumin, resveratrol, and quercetin were loaded on different nanoemulsion-based delivery systems to improve the efficacy of their lipophilic nature [151]. On the other hand, liposomes have also been used as delivery systems for polyphenols; they can protect polyphenols against hydrolysis by enzymes and acids in the stomach; thus, polyphenols can reach their target tissues [117]. The interiors of hydrogels contain a porous three-dimensional polymer network that can hold about 90% of water; thus, hydrogels have been used to enhance the stability and bioavailability of polyphenols. A study showed that injectable hydrogels based on curcumin could improve the effectiveness of this polyphenol against cancer cells [152]. In general, modern encapsulation systems are currently leading to a new era of developing diet-based medicine. As the demand for polyphenol-based nutritional supplements and edibles grows, the utilization of encapsulation systems also grows.

9. Effects of Processing on Polyphenol Content of Foods and Ultimate Impact on Anti-Obesity Potential of the Final Product

Food processing can influence the metabolites in foods (their content and bioavailability). Effects of traditional technologies such as thermal processing and fermentation on the polyphenols content of food have been evaluated, and the eventual impact on the anti-obesity potential of the final products has been established [153–155]. In the literature, fermentation of tea leaves using *L. paracasei* subsp. *paracasei* NTU 101 was able to enhance the content of polyphenols such as EGC (107.9 versus 159.6 µg/mL), EGCG (482.4 versus 968.3 µg/mL), and chlorogenic acid (38.5 versus 46.9 µg/mL) compared to the unfermented [153]. The final product of the fermented tea leaves showed better anti-obesity efficacy compared to the unfermented tea [153]. Thermal processing significantly improved the polyphenolic components of sorghum, thereby enhancing their lipase inhibitory ability [154,155]. Heat treatment, microwave processing, and fermentation can improve the levels of polyphenols in foods by triggering the release of bound phenolic content into the food matrix. Nevertheless, in some cases, heat treatment and excessive microwave processing may degrade phenolic acids, thus, reducing their amounts in the final products [154,155]. Similarly, fermentation can also result in the loss of polyphenol content in foods; microorganisms used as starter cultures may use polyphenols in foods as a source of nutrients for their growth or even bioconvert them into other compounds [154]. As a result, studies have often reported conflicting results concerning the effects of processing techniques on polyphenols. Aloo et al. reported that traditional seed processing methods, such as germination, can significantly improve the polyphenolic content of foods such as buckwheat and red cabbage sprouts. The sprouts were reported to possess better inhibitory activity against lipase and alpha-glucosidase enzymes as compared to non-sprouted seeds [156]. On the other hand, emerging technologies such as ultrasound processing, high hydrostatic pressure, pulsed electric field, ultrasound, ohmic heating, high-pressure carbon dioxide processing, and irradiation are being investigated as alternatives to traditional methods for obtaining promising products with improved polyphenol contents. Compared to conventional ones, these novel technologies tend to retain most of the polyphenols and organoleptic characteristics of the final products elsewhere [154]. Thus, processing technologies have great potential to produce food products with improved polyphenol contents and anti-obesity activities. A rather in-depth analysis of the effects of these technologies on the polyphenol content of food has been discussed elsewhere [154]. In the future, the development of functional foods for the prevention and/or treatment of obesity will take advantage of processing techniques to improve the health potential of foods.

10. Drawbacks of Polyphenols as Phytonutrients in Foods: Benefits versus Risks

Although studies have confirmed the health benefits of polyphenols, findings from in vitro cell models, in vivo animal models, and human clinical assessments remain inconclusive. Even though experimental studies have provided extremely valuable information on the beneficial effects of dietary polyphenols, great care is required when interpreting the information obtained from these assessments. First of all, a critical problem that often compromises these studies is the safety of polyphenols. While plant bioactive compounds are generally considered safe because of their long consumption history, it is becoming increasingly apparent that some could have adverse health effects in vulnerable groups or when consumed at higher concentrations [157]. Studies on the safety of polyphenols have discovered that polyphenol consumption may be safe or unsafe depending on factors, mainly intake level and duration. Evidence indicates that taking some polyphenols for an extended period at high doses may lead to severe toxic effects. Yamakoshi et al. described a lack of adverse effects when 2–4 g/kg proanthocyanin-rich grape seed extracts were administered to rats [27]. However, in the study, Yamakoshi et al. discovered lethal doses of proanthocyanin-rich grape seed extracts at above 4 g/kg consumed for 14 days [27]. Grape seed polyphenolic extract (GSPE) was also safe in a 90-day subchronic toxicity study involving an animal model, with treatment doses ranging from 200 mg/kg/day to 215 mg/kg/day [158]. Above the amount, however, GSPE triggered adverse effects upon its consumption [158]. The recommended intake of isoflavones is 50 mg per day [159]. It was reported that the total plasma isoflavone levels range between 0.055 $\mu\text{mol/L}$ and 5 $\mu\text{mol/L}$, and the daily intake from most Western diets is estimated at 0.2–5 mg/day [159]. These levels of intake are regarded as safe. However, a high intake of isoflavones, above the levels (0.2–5 mg per day), has been associated with reduced fertility and increased anti-luteinizing hormone effects [159]. Similarly, while the anti-obesity activity of catechin and its derivatives is well known, there is an increasing body of evidence that links high levels of these compounds with pro-oxidative effects due to their reaction with peroxide in the body [157].

Therefore, it is eminent that despite their reported positive health impacts, polyphenols may also pose a significant health risk. Meanwhile, considering the safety of phenolic compounds, as with most substances, the dose and duration of intake distinguish a poison from a remedy. Also, it is essential to recognize that the usage of these compounds depends on their benefits versus risks [157]. Thus, even though the risk of consuming high doses of polyphenols from foods is generally low, the underlying long-term effects of consuming small amounts in the body must be considered. It is crucial to note that without a complete understanding of the benefits versus risks of polyphenol intake, their addition to foods cannot be adequately justified. Thus, food producers should perform proper assessments before undertaking supplementation trials of polyphenolic compounds to uncover their safe levels. Currently, only a limited number of reports from human clinical trials are available describing the safety of polyphenols with anti-obesity effects (Table 7).

Table 7. Studies investigating the safety of polyphenols in human clinical trials.

Polyphenol	Subject Description	Dosage	Side Effect	References
Resveratrol (RV)	40 healthy volunteers aged 18–80 years	Participants took oral resveratrol (single doses of 0.5, 1, 2.5, or 5 g) per day for 1 week.	An intake of up to one dose of 5 g of resveratrol was safe, with only minor adverse events in some cases.	[160]
Sinetrol-XPur (polyphenolic citrus dry extract)	95 healthy overweight volunteers (55 women and 40 men), age: 22–45 years, BMI: 26–29.9 kg/m ²	Subjects consumed two capsules of citrus polyphenolic extract containing orange, grapefruit, sweet orange, and guarana for 12 weeks	Mild effect, such as a slight increase in cardiac rate, was observed	[83]

Table 7. Cont.

Polyphenol	Subject Description	Dosage	Side Effect	References
Resveratrol	24 overweight patients, median age: 66.5 years	Participants took 5.0 g resveratrol per day for 4 months	Serious adverse effects, including nausea, diarrhea, vomiting, and fatigue	[161]
Resveratrol	62 participants (men and women)	Participants consumed 250 mg daily for 3 months	Improved glycemic control with no observable side effects	[162]
Epicatechin	age:18–50 years BMI: 19–30 kg/m ²	Subjects consumed 250 mg of cocoa flavanols; 40 mg of epicatechin for 14 days	Improved body weight parameters with no adverse events observed	[163]
Ellagitannin	64 overweight individuals, age: 40–70 years, BMI: 25–32 kg/m ²	Subjects consumed 710 mg per day of a pomegranate ellagitannin-enriched polyphenol extract.	No serious adverse events on the subject upon the intake	[164]
Polyphenon E	40 healthy participants with Fitzpatrick skin types II or III, age: ≥18 year	Participants took 800 mg polyphenol E once per day for 2 weeks	Adverse events, including stomach upset, nausea, heartburn, stomach pain, dizziness, headache, and muscle pain, were observed during the 4-week treatment period	[165]
Polyphenols-rich green tea	17 healthy volunteers, age: 41 ± 9 years BMI 26.7 ± 3.3 kg/m ² ,	Participants consumed tea containing 119 mg polyphenols (epicatechin, 5 mg; epigallocatechin, 47 mg; epigallocatechingallate, 25 mg; epicatechingallate, 14 mg; galloatechingallate, 8 mg; catechingallate, 3 mg; catechin, 1 mg; galloatechin, 9 mg; and ellagic acid, 7 mg) and 19 mg caffeine per day for 3 weeks	The daily consumption of green tea polyphenols, even at high dose levels, was safe. No effects on cardiovascular risk biomarkers screened	[166]
Curcumin	10 healthy male volunteers aged 20–26 years. Weight: 50–75 kg	Participants consumed beverages formulated with 2 g of curcumin	Improved serum concentration without any toxic effect observed	[167]
EGCG and α-glucosyl hesperidin (gH)	60 healthy males and females aged: 30–75 years	Subjects were given green tea, 178 mg gH and 146 mg EGCG per day for 12 weeks	The amount of EGCG and gH consumed effectively reduced body weight with no adverse effects	[168]
Juçara fruit polyphenols	35 adults known to be obese (men and women) aged 31–59 years. BMI: 30–39.9 kg/m ²	Subjects consumed 5 g of pulp powder per day for 6 weeks	No toxic effects were observed. Authors' conclusion: safe for consumption	[169]
Hibiscus and lemon verbena polyphenols	54 overweight subjects, age: 30–75 years BMI: 25–34.9 kg m ⁻²	500 mg of <i>Lippia citriodora</i> (35%) and <i>Hibiscus sabdariffa</i> (65%) per day for 2 months was taken by the studied subjects	No toxic effects were reported	[170]
Green tea (containing majorly, catechins)	35 subjects with obesity and metabolic syndrome	Subjects consumed green tea (four cups/day) or green tea extract (two capsules/day) for 8 weeks.	Improved obesity-related parameters without any observable side effect	[89]
<i>Lippia Citriodora</i> and <i>Hibiscus Sabdariffa</i> extract (Lc-Hs)	33 Volunteers (male and female), age: 18–65 years, BMI: 25–34.9 kg/m ²	Oral administration of two capsules/day, each capsule containing 250 mg for 60 days	The supplementation with the Lc-Hs extract decreased appetite sensation; no toxicity was observed upon consumption	[171]
High dose of resveratrol	24 obese but healthy volunteers (men), age: 18–70 years, BMI >30 kg/m ²	Subjects consumed 500 mg/day of resveratrol for 4 weeks	Improved key obesity indicators (total and lean body mass, total body fat mass, or visceral and abdominal subcutaneous fat). No adverse effects were observed.	[172]
Catechin-enriched green tea	33 obese subjects (18 men, 15 women), age: 20–65 years, waist circumference: ≥80 cm (women) or 90 cm (men)	Subjects drank a 350-mL bottle of beverage after lunchtime within 30 min daily for 12 weeks.	Adverse events such as changes in stools, abdominal discomfort, and appetite were associated with catechin-enriched green tea consumption	[173]
Acacia bark-derived proanthocyanidins		Participants took proanthocyanidins derived from acacia bark (245 mg/day for 12 weeks)	No side effects or adverse events were observed upon the consumption	[174]
Gallic acid	105 healthy subjects age: 18–60 years, BMI: 25–35 kg/m ²	Subjects took a 300 mg/1.2 g NT-GA combination or 600 mg/2.4 g/day NT-GA for 24 weeks.	NT-GA consumption was well tolerated but was ineffective in causing weight loss or limiting food intake	[175]

RV, Resveratrol; GA, gallic acid; EGCG, epigallocatechin gallate; BMI, body mass index; NT is an herbal supplement derived from a water extract of rhubarb, ginger, astragalus, red sage, and turmeric.

To demonstrate the bioactivity of naturally occurring compounds in foods, it is essential to define a logical chain of events that may affect their bioavailability, chemistry, and physiology. Thus, another essential aspect that should be considered when evaluating the bioactivities of polyphenols and polyphenol-rich foods is the effect of processing on the structure and bioavailability of initially present polyphenols in foods. Most polyphenols are heat-labile compounds and susceptible to light, pH variation, and enzymatic degradation. For example, the exposure of anthocyanins to high temperatures during food processing may degrade these compounds into other products (phenolic acids and phloroglucinaldehyde) [176]. The oven-baking processing can cause a degradation of chlorogenic acid [177], while boiling can significantly degrade quercetin in onions and tomatoes [178]. Hence, retaining the original phenolic compounds in fortified foods is complex and may require novel processing techniques, such as high hydrostatic pressure and irradiation, which are quite expensive [4].

Furthermore, polyphenol incorporation in processed foods may lead to a potential negative influence on the sensory properties (color, texture, and flavor) of food products if processing conditions are not controlled. Since most of these compounds are sensitive to heat and other environmental factors, they may react with other food components or be oxidized to form different products, such as quinones which may negatively affect food acceptability among consumers [179]. For instance, Aloo et al., and Shen et al., reported that an unusual dark color affecting the palatability of hemp-based foods is attributed to polymerization and oxidation reactions of indigenous hemp's polyphenolic compounds and chlorophyll during processing [180,181]. So, prolonged exposure to these conditions can significantly impact polyphenols or polyphenol-rich foods, even though this effect is often ignored. This transformation process may also affect the biological functions of polyphenols, rendering them ineffective, or may even change their chemistry leading to harmful effects. Finally, the two-way interaction between gut microbiota and polyphenols leads to the biotransformation of these compounds. This process may either positively or negatively affect their bioavailability since it affects the relative abundance of beneficial gut microbiota [22].

11. Research Limitations

Findings have demonstrated that polyphenols can also play a pivotal role in health. However, for several reasons, it has been challenging to establish the benefits of polyphenol consumption in humans fully. First, the polyphenol content of foods is so diverse and varies. In some cases, there is inadequate information regarding their levels of particular foods; thus, it is difficult to understand their total intake fully. Despite many mechanistic studies using pure compounds or natural plant extracts to elucidate the amount of polyphenols in food products, research has only offered limited information related to the polyphenol content, bioavailability, and extent of absorption in foods [182]. Some of these studies have also reported varying levels of polyphenols in some foods, making it challenging to add regulatory recommendations to functional food labels [183]. Conclusions on the exact level of polyphenols in regular diets remain a subject for studies. Therefore, unlike synthetic drugs, currently, there is no legislation or laws regulating polyphenol supplementation and consumption.

Second, *in vitro* and *in vivo* studies have demonstrated that dietary supplementation with plant products rich in polyphenols is a potentially viable nutritional method for the prevention of obesity. Nevertheless, the full potential of some of these foods in humans remains partially known since most of the outcomes from studies display variability and inconsistencies in clinical trials of different subjects [184]. For example, it was reported that almost all studies conducted with Asian subjects had revealed a positive outcome on the anti-obesity effects of tea extract [184]. However, clinical trials using Caucasian subjects provided mixed outcomes on the effectiveness of tea extract on obesity [184]. Therefore, human trials have often shown inconsistent results, making it difficult to make accurate conclusions on the efficacy of polyphenols against diseases. Factors such as different study

designs, length of study, doses used, and choice of subjects (based on age, gender, and ethnicity) may cause this variation [2].

Third, in clinical trials, some polyphenols often fail to produce the results observed in either in vitro/ex vivo or in vivo studies. While the cause of this is not fully known, it is speculated that either change in mechanisms of action, the mode through which the compound is taken, or factors related to absorption may affect the efficacy of polyphenols in clinical trials [2]. Moreover, reports on the safety of the same polyphenol may also vary between in vitro, in vivo, and human clinical trials. Poulsen and colleagues indicated that while data obtained from rodent models discourage consuming high doses of resveratrol, results from human clinical trials support the safety of resveratrol consumption even at higher doses [172]. The lack of agreement between the findings from the cell, animal, and human trials raises doubts about the justification of polyphenols as a human nutritional supplement or an ingredient in food-targeting disorders [172].

Fourth, studies have often ignored the significance of the relationship between polyphenol doses and the duration of intake in human trials. Clinical trials need to evaluate the links between different doses of polyphenols and the duration of intake. This relationship might offer vital evidence to understand the effect of polyphenols on body weight within a specific period to avoid downstream effects resulting from an overdose due to long consumption. Another important aspect of dose that often compromises in vitro experimental models is the concentrations applied. The doses used in in vitro studies should be designed to reflect real life. However, while the tested concentrations in the in vitro studies commonly range from low $\mu\text{mol/L}$ to mmol/L , the concentrations of plasma metabolites, after a normal dietary intake, hardly exceed nmol/L [185]. Thus, high doses used in vitro can “force” a conclusion on the outcome, which may not reflect in the in vivo or clinical trial results. Finally, it has been revealed that fortified foods might be more energy-dense rather than nutrient-dense [183]. This may offset any potential anti-obesogenic effects of phenolic compounds and potentially result in weight gain [183]. Thus, despite numerous studies highlighting their potential benefits, research has also shown ambiguous links between polyphenol fortification and obesity, making it difficult to recommend them effectively for food fortification [183].

12. Perspectives

Polyphenols are essential ingredients in the food industry. Given the global rise in demand for functional foods, diversifying into these ingredients can add some resilience to the increasing impact of obesity as a nutritional approach. The following highlighted gaps need to be addressed to enhance understanding of the health benefits of polyphenols.

- i. In the study of plant phyto-ingredients, human and animal experiments are the most relevant in clinical nutrition but possess certain limitations. In the research on the health functions of plant metabolites, the two models have sometimes shown differences in the outcome. In most cases, the differences in the genetic composition between humans and mice are the causes of this variation [160]. Given these potential inconsistencies and to enable the public to make informed choices on polyphenol consumption, future research is needed to be more robust in clinical trials using human subjects to assess the anti-obesity effectiveness of polyphenols instead of relying on in vitro or animal findings for conclusions;
- ii. The biological activity of polyphenols can be affected by various factors. The length of intake and mode of intake of polyphenols are key determinants of polyphenols' biological activity [182]. However, most current studies have largely ignored the significance of the correlation between polyphenol intake and the length of intake. Furthermore, as already been mentioned, polyphenols doses administered during clinical trials are often higher than in the common diet [182]. However, only a few human studies have considered this factor in drawing a scientific substantiation for the relative claimed effects of polyphenols. In future research, it is essential to

- assess the relevance of these factors in the anti-obesity potential of polyphenol-rich foods to offer a verifiable claim on the health effects of polyphenols;
- iii. Although trials have shown a correlation between polyphenol consumption and a reduction in risk factors for chronic diseases, discrepancies in explaining their positive effects have been found due to their low content in most daily diets as well as bioavailability. More studies are needed to find safe and effective methods to incorporate polyphenols in foods to improve their levels consumed in diets and to enhance the bioavailability to realize similar outcomes observed in *in vitro*, *in vivo*, and clinical trials studies. Nanocarriers are a potential technology for polyphenol encapsulation that could enhance their bioavailability, solubility and stability at their target sites in the body. In the current settings, most nanotechnology reports have addressed diseases such as cancer, but none of the studies have been reported for polyphenols targeting obesity. Future research needs to evaluate the effectiveness of encapsulated polyphenols against obesity development, both in animal and human trials, not just *in vitro*;
 - iv. The translation of food composition into intakes of a specific dietary compound is often achieved using food composition databases. However, for polyphenols, the approach needs to be revised since the currently available databases contain limited information regarding the diversity and concentration of phenolic compounds in plant foods. These limitations arise mainly because, unlike most nutrients, there has been a narrow systematic approach to comprehensively characterize and quantify the diverse polyphenols in plant foods using standardized analytical methods. Moreover, much of the available information has been assembled solely from heterogeneous sources, in which the original food sampling and description are still being investigated. Furthermore, the complexity arises due to the uneven distribution of polyphenolic compounds in different parts of plants and the loss of specific polyphenols during food processing. For example, in apples, quercetin is mainly found in the peel; however, peeled fruit contains no quercetin. Similarly, most polyphenols in wheat grain are located primarily in the outer layers and are usually lost during the refining process of the flour. Further research is required to expand our current knowledge regarding alternative dietary assessment methods that could help overcome these challenges;
 - v. Finally, to establish firm evidence for the health effects of dietary polyphenol consumption, it is essential to have quantitative information regarding their dietary intake on food labels. This is particularly essential for enriched foods or foods that are known to contain high amounts of these compounds. The usefulness of such information is that consumers can have a planned dietary intake based on specific foods. Thus, similar to other known nutrients and drugs, in the future, food records and labels for polyphenols need to be developed to allow consumers to quickly assess total intake and required precautionary measures accurately.

13. Concluding Remarks

Evidence from cellular, animal and human studies indicates that consuming polyphenols in diet or as a supplement enhances protection against obesity. Anti-obesity activities of polyphenols may occur through mechanisms including enzyme inhibition, suppression of neuro-hormones related to food intake and satiety, and induction of mitochondrial biogenesis. Since polyphenols demonstrate great anti-obesity potential, screening for polyphenol-rich foods with anti-obesity effects but fewer adverse reactions in humans will likely offer a novel and effective therapeutic strategy to fight obesity. A comprehensive safety evaluation is needed to ascertain consumer safety of polyphenols consumption in foods. Rigorous assessment of these compounds in human trials will provide evidence-based results that will facilitate the incorporation of natural phenolic compounds in functional foods or as supplements to help fight the growing problem of obesity.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/antiox12020416/s1>.

Author Contributions: S.-O.A.: Conceptualization, Methodology, Investigation, Formal analysis, Writing—original draft; F.K.O., N.-H.K. and S.M.K.: Proofreading and editing; D.-H.O.: Conceptualization and Supervision. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported and funded by the Cooperative Research Program for Agriculture Science and Technology Development (Project No. PJ0145652021), Rural Development Administration, Republic of Korea.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sergent, T.; Vanderstraeten, J.; Winand, J.; Beguin, P.; Schneider, Y.-J. Phenolic compounds and plant extracts as potential natural anti-obesity substances. *Food Chem.* **2012**, *135*, 68–73. [\[CrossRef\]](#)
2. Boccellino, M.; D'Angelo, S. Anti-obesity effects of polyphenol intake: Current status and future possibilities. *Int. J. Mol. Sci.* **2020**, *21*, 5642. [\[CrossRef\]](#)
3. WHO. *Adolescent Obesity and Related Behaviours: Trends and Inequalities in the WHO European Region, 2002–2014*; WHO: Geneva, Switzerland, 2017.
4. Singh, M.; Thrimawithana, T.; Shukla, R.; Adhikari, B. Managing obesity through natural polyphenols: A review. *Future Foods* **2020**, *1*, 100002. [\[CrossRef\]](#)
5. Dietrich, M.O.; Horvath, T.L. Limitations in anti-obesity drug development: The critical role of hunger-promoting neurons. *Nat. Rev. Drug Discov.* **2012**, *11*, 675–691.
6. Mayer, M.A.; Hocht, C.; Puyó, A.; Taira, C.A. Recent advances in obesity pharmacotherapy. *Curr. Clin. Pharmacol.* **2009**, *4*, 53–61. [\[CrossRef\]](#)
7. Jepsen, M.M.; Christensen, M.B. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. *Expert Opin. Emerg. Drugs* **2021**, *26*, 231–243.
8. Cercato, C.; Roizenblatt, V.; Leança, C.; Segal, A.; Lopes Filho, A.; Mancini, M.; Halpern, A. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. *Int. J. Obes.* **2009**, *33*, 857–865.
9. Wigal, T.L.; Newcorn, J.H.; Handal, N.; Wigal, S.B.; Mulligan, I.; Schmith, V.; Konofal, E. A double-blind, placebo-controlled, phase II study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit/hyperactivity disorder (ADHD). *CNS Drugs* **2018**, *32*, 289–301. [\[CrossRef\]](#)
10. Stoops, W.W.; Strickland, J.C.; Hays, L.R.; Rayapati, A.O.; Lile, J.A.; Rush, C.R. Safety and tolerability of intranasal cocaine during phendimetrazine maintenance. *Psychopharmacology* **2016**, *233*, 2055–2063.
11. Kang, J.; Park, C.Y.; Kang, J.; Park, Y.W.; Park, S. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. *Diabetes Obes. Metab.* **2010**, *12*, 876–882.
12. Shirai, K.; Fujita, T.; Tanaka, M.; Fujii, Y.; Shimomasuda, M.; Sakai, S.; Samukawa, Y. Efficacy and safety of lipase inhibitor orlistat in Japanese with excessive visceral fat accumulation: 24-week, double-blind, randomized, placebo-controlled study. *Adv. Ther.* **2019**, *36*, 86–100. [\[CrossRef\]](#)
13. Toplak, H.; Hamann, A.; Moore, R.; Masson, E.; Gorska, M.; Vercruyse, F.; Sun, X.; Fitchet, M. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study. *Int. J. Obes.* **2007**, *31*, 138–146. [\[CrossRef\]](#)
14. O'neil, P.M.; Smith, S.R.; Weissman, N.J.; Fidler, M.C.; Sanchez, M.; Zhang, J.; Raether, B.; Anderson, C.M.; Shanahan, W.R. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. *Obesity* **2012**, *20*, 1426–1436. [\[CrossRef\]](#)
15. Sramek, J.; Leibowitz, M.; Weinstein, S.; Rowe, E.; Mendel, C.; Levy, B.; McMahon, F.; Mullican, W.; Toth, P.; Cutler, N. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β -adrenergic blocking agents: A placebo-controlled, double-blind, randomised trial. *J. Hum. Hypertens.* **2002**, *16*, 13–19.
16. Greenway, F.L.; Fujioka, K.; Plodkowski, R.A.; Mudaliar, S.; Guttadauria, M.; Erickson, J.; Kim, D.D.; Dunayevich, E.; Group, C.-I.S. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* **2010**, *376*, 595–605. [\[CrossRef\]](#)
17. Ji, L.; Onishi, Y.; Ahn, C.W.; Agarwal, P.; Chou, C.W.; Haber, H.; Guerrettaz, K.; Boardman, M.K. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. *J. Diabetes Investig.* **2013**, *4*, 53–61.
18. Pinget, M.; Goldenberg, R.; Niemoeller, E.; Muehlen-Bartmer, L.; Guo, H.; Aronson, R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). *Diabetes Obes. Metab.* **2013**, *15*, 1000–1007. [\[CrossRef\]](#)

19. O'Neil, P.M.; Birkenfeld, A.L.; McGowan, B.; Mosenzon, O.; Pedersen, S.D.; Wharton, S.; Carson, C.G.; Jepsen, C.H.; Kabisch, M.; Wilding, J.P. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet* **2018**, *392*, 637–649.
20. Reusch, J.; Stewart, M.; Perkins, C.; Cirkel, D.; Ye, J.; Perry, C.; Reinhardt, R.; Bode, B. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. *Diabetes Obes. Metab.* **2014**, *16*, 1257–1264.
21. Umpierrez, G.; Povedano, S.T.; Manghi, F.P.; Shurzinske, L.; Pechtnr, V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). *Diabetes Care* **2014**, *37*, 2168–2176.
22. Ozdal, T.; Sela, D.A.; Xiao, J.; Boyacioglu, D.; Chen, F.; Capanoglu, E. The reciprocal interactions between polyphenols and gut microbiota and effects on bioaccessibility. *Nutrients* **2016**, *8*, 78. [[CrossRef](#)]
23. Akhlaghi, M.; Ghobadi, S.; Hosseini, M.M.; Gholami, Z.; Mohammadian, F. Flavanols are potential anti-obesity agents, a systematic review and meta-analysis of controlled clinical trials. *Nutr. Metab. Cardiovasc. Dis.* **2018**, *28*, 675–690. [[CrossRef](#)]
24. Wu, S.; Tian, L. A new flavone glucoside together with known ellagitannins and flavones with anti-diabetic and anti-obesity activities from the flowers of pomegranate (*Punica granatum*). *Nat. Prod. Res.* **2019**, *33*, 252–257. [[CrossRef](#)]
25. Corrêa, T.A.F.; Rogero, M.M.; Hassimotto, N.M.A.; Lajolo, F.M. The two-way polyphenols-microbiota interactions and their effects on obesity and related metabolic diseases. *Front. Nutr.* **2019**, *6*, 188. [[CrossRef](#)]
26. Otton, R.; Bolin, A.P.; Ferreira, L.T.; Marinovic, M.P.; Rocha, A.L.S.; Mori, M.A. Polyphenol-rich green tea extract improves adipose tissue metabolism by down-regulating miR-335 expression and mitigating insulin resistance and inflammation. *J. Nutr. Biochem.* **2018**, *57*, 170–179. [[CrossRef](#)]
27. Yamakoshi, J.; Saito, M.; Kataoka, S.; Kikuchi, M. Safety evaluation of proanthocyanidin-rich extract from grape seeds. *Food Chem. Toxicol.* **2002**, *40*, 599–607. [[CrossRef](#)]
28. Lee, H.; Jeong, J.H.; Ryu, J.-H. Lignan from *Alnus japonica* inhibits adipocyte differentiation via cell cycle and FOXO1 regulation. *Molecules* **2020**, *25*, 3346. [[CrossRef](#)]
29. Mir, S.A.; Shah, M.A.; Ganai, S.A.; Ahmad, T.; Gani, M. Understanding the role of active components from plant sources in obesity management. *J. Saudi Soc. Agric. Sci.* **2019**, *18*, 168–176. [[CrossRef](#)]
30. Adaim, A.; Zhang, J.; Lauren, D.; Stanley, R.; Skinner, M. Polyphenols and health: Using cell-based assays to aid in the development of new functional foods. *Asia Pac. J. Clin. Nutr.* **2005**, *14*, S106.
31. Ravi, A.; Perera, C.; Quek, S.; Sun-Waterhouse, D. Physico-chemical properties of bread dough fortified with fruit fibers and phenolic antioxidants. In Proceedings of the Oral Presentation at the 2009 Institute of Food Technologists (IFT) Annual Meeting & Food Expo, Anaheim, CA, USA, 6–9 June 2009.
32. Bora, A.F.M.; Ma, S.; Li, X.; Liu, L. Application of microencapsulation for the safe delivery of green tea polyphenols in food systems: Review and recent advances. *Food Res. Int.* **2018**, *105*, 241–249.
33. Sun-Waterhouse, D. The development of fruit-based functional foods targeting the health and wellness market: A review. *Int. J. Food Sci. Technol.* **2011**, *46*, 899–920. [[CrossRef](#)]
34. Kiss, A.; Takács, K.; Nagy, A.; Nagy-Gasztonyi, M.; Cserhalmi, Z.; Naár, Z.; Halasi, T.; Csáki, J.; Némedi, E. In vivo and in vitro model studies on noodles prepared with antioxidant-rich pseudocereals. *J. Food Meas. Charact.* **2019**, *13*, 2696–2704.
35. Mayneris-Perxachs, J.; Alcaide-Hidalgo, J.M.; de la Hera, E.; del Bas, J.M.; Arola, L.; Caimari, A. Supplementation with biscuits enriched with hesperidin and naringenin is associated with an improvement of the Metabolic Syndrome induced by a cafeteria diet in rats. *J. Funct. Foods* **2019**, *61*, 103504. [[CrossRef](#)]
36. Coe, S.; Ryan, L. White bread enriched with polyphenol extracts shows no effect on glycemic response or satiety, yet may increase postprandial insulin economy in healthy participants. *Nutr. Res.* **2016**, *36*, 193–200. [[CrossRef](#)]
37. Serrano, A.; González-Sarrias, A.; Tomás-Barberán, F.A.; Avellaneda, A.; Gironés-Vilaplana, A.; Nieto, G.; Ros-Berruezo, G. Anti-inflammatory and antioxidant effects of regular consumption of cooked ham enriched with dietary phenolics in diet-induced obese mice. *Antioxidants* **2020**, *9*, 639.
38. Colantuono, A.; Ferracane, R.; Vitaglione, P. In vitro bioaccessibility and functional properties of polyphenols from pomegranate peels and pomegranate peels-enriched cookies. *Food Funct.* **2016**, *7*, 4247–4258. [[CrossRef](#)]
39. Bajerska, J.; Mildner-Szkudlarz, S.; Walkowiak, J. Effects of rye bread enriched with green tea extract on weight maintenance and the characteristics of metabolic syndrome following weight loss: A pilot study. *J. Med. Food* **2015**, *18*, 698–705.
40. Bajerska, J.; Mildner-Szkudlarz, S.; Pruszyńska-Oszmalek, E. May rye bread enriched with green tea extract be useful in the prevention of obesity in rats? *Acta Aliment.* **2013**, *42*, 69–78.
41. Macho-González, A.; López-Oliva, M.E.; Merino, J.J.; García-Fernández, R.A.; Garcimartín, A.; Redondo-Castillejo, R.; Bastida, S.; Sánchez-Muniz, F.J.; Benedí, J. Carob fruit extract-enriched meat improves pancreatic beta-cell dysfunction, hepatic insulin signaling and lipogenesis in late-stage type 2 diabetes mellitus model. *J. Nutr. Biochem.* **2020**, *84*, 108461.
42. Hsu, T.; Kusumoto, A.; Abe, K.; Hosoda, K.; Kiso, Y.; Wang, M.; Yamamoto, S. Polyphenol-enriched oolong tea increases fecal lipid excretion. *Eur. J. Clin. Nutr.* **2006**, *60*, 1330–1336. [[CrossRef](#)]
43. Isganaitis, E.; Lustig, R.H. Fast food, central nervous system insulin resistance, and obesity. *Arterioscler. Thromb. Vasc. Biol.* **2005**, *25*, 2451–2462.

44. Sigal, R.J.; El-Hashimy, M.; Martin, B.C.; Soeldner, J.S.; Krolewski, A.S.; Warram, J.H. Acute postchallenge hyperinsulinemia predicts weight gain: A prospective study. *Diabetes* **1997**, *46*, 1025–1029. [[CrossRef](#)]
45. Mayer, J. Regulation of energy intake and the body weight: The glucostatic theory and the lipostatic hypothesis. *Ann. N. Y. Acad. Sci.* **1955**, *63*, 15–43. [[CrossRef](#)]
46. Lim, K.J.; Bisht, S.; Bar, E.E.; Maitra, A.; Eberhart, C.G. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. *Cancer Biol. Ther.* **2011**, *11*, 464–473.
47. Xiang, L.; Wu, Q.; Cheng, L.; Sun, K.; Li, J.; Yoshida, M.; Qi, J. Leptin and adiponectin signaling pathways are involved in the antiobesity effects of peanut skin extract. *Oxidative Med. Cell. Longev.* **2019**, *2019*, 2935315.
48. Ardid-Ruiz, A.; Ibars, M.; Mena, P.; Del Rio, D.; Muguerza, B.; Bladé, C.; Arola, L.; Aragonès, G.; Suárez, M. Potential involvement of peripheral leptin/STAT3 signaling in the effects of resveratrol and its metabolites on reducing body fat accumulation. *Nutrients* **2018**, *10*, 1757.
49. Badshah, H.; Ullah, I.; Kim, S.E.; Kim, T.-h.; Lee, H.Y.; Kim, M.O. Anthocyanins attenuate body weight gain via modulating neuropeptide Y and GABAB1 receptor in rats hypothalamus. *Neuropeptides* **2013**, *47*, 347–353.
50. Buchholz, T.; Melzig, M.F. Polyphenolic compounds as pancreatic lipase inhibitors. *Planta Med.* **2015**, *81*, 771–783.
51. McDougall, G.J.; Kulkarni, N.N.; Stewart, D. Berry polyphenols inhibit pancreatic lipase activity in vitro. *Food Chem.* **2009**, *115*, 193–199.
52. Griffiths, D.W. The inhibition of digestive enzymes by polyphenolic compounds. In *Nutritional and Toxicological Significance of Enzyme Inhibitors in Foods*; Springer: Berlin/Heidelberg, Germany, 1986; pp. 509–516.
53. Othman, Z.A.; Wan Ghazali, W.S.; Noordin, L.; Mohamed, M. Phenolic compounds and the anti-atherogenic effect of bee bread in high-fat diet-induced obese rats. *Antioxidants* **2020**, *9*, 33. [[CrossRef](#)]
54. Brusselmans, K.; De Schrijver, E.; Heyns, W.; Verhoeven, G.; Swinnen, J.V. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. *Int. J. Cancer* **2003**, *106*, 856–862.
55. Kim, N.-H.; Jegal, J.; Kim, Y.N.; Heo, J.-D.; Rho, J.-R.; Yang, M.H.; Jeong, E.J. Chokeberry extract and its active polyphenols suppress adipogenesis in 3T3-L1 adipocytes and modulates fat accumulation and insulin resistance in diet-induced obese mice. *Nutrients* **2018**, *10*, 1734. [[CrossRef](#)]
56. Xie, H.; Sun, L.; Lodish, H.F. Targeting microRNAs in obesity. *Expert Opin. Ther. Targets* **2009**, *13*, 1227–1238. [[CrossRef](#)]
57. Rocha, A.; Bolin, A.P.; Cardoso, C.A.L.; Otton, R. Green tea extract activates AMPK and ameliorates white adipose tissue metabolic dysfunction induced by obesity. *Eur. J. Nutr.* **2016**, *55*, 2231–2244. [[CrossRef](#)]
58. Pollard, A.E.; Martins, L.; Muckett, P.J.; Khadayate, S.; Bornot, A.; Clausen, M.; Admyre, T.; Bjursell, M.; Fiadeiro, R.; Wilson, L. AMPK activation protects against diet-induced obesity through Ucp1-independent thermogenesis in subcutaneous white adipose tissue. *Nat. Metab.* **2019**, *1*, 340–349. [[CrossRef](#)]
59. Fang, C.; Kim, H.; Noratto, G.; Sun, Y.; Talcott, S.T.; Mertens-Talcott, S.U. Gallotannin derivatives from mango (*Mangifera indica* L.) suppress adipogenesis and increase thermogenesis in 3T3-L1 adipocytes in part through the AMPK pathway. *J. Funct. Foods* **2018**, *46*, 101–109. [[CrossRef](#)]
60. dos Santos, T.W.; Cristina Pereira, Q.; Teixeira, L.; Gambero, A.; Villena, J.A.; Lima Ribeiro, M. Effects of polyphenols on thermogenesis and mitochondrial biogenesis. *Int. J. Mol. Sci.* **2018**, *19*, 2757.
61. de Mello, A.H.; Costa, A.B.; Engel, J.D.G.; Rezin, G.T. Mitochondrial dysfunction in obesity. *Life Sci.* **2018**, *192*, 26–32.
62. Fernandez-Marcos, P.J.; Auwerx, J. Regulation of PGC-1 α , a nodal regulator of mitochondrial biogenesis. *Am. J. Clin. Nutr.* **2011**, *93*, 884S–890S. [[CrossRef](#)]
63. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 α . *Cell* **2006**, *127*, 1109–1122.
64. Yoneshiro, T.; Aita, S.; Matsushita, M.; Kameya, T.; Nakada, K.; Kawai, Y.; Saito, M. Brown adipose tissue, whole-body energy expenditure, and thermogenesis in healthy adult men. *Obesity* **2011**, *19*, 13–16.
65. Zhang, Z.; Di Yang, J.X.; Zhou, J.; Cao, H.; Che, Q.; Bai, Y.; Guo, J.; Su, Z. Non-shivering Thermogenesis Signalling Regulation and Potential Therapeutic Applications of Brown Adipose Tissue. *Int. J. Biol. Sci.* **2021**, *17*, 2853.
66. Han, X.; Guo, J.; You, Y.; Yin, M.; Liang, J.; Ren, C.; Zhan, J.; Huang, W. Vanillic acid activates thermogenesis in brown and white adipose tissue. *Food Funct.* **2018**, *9*, 4366–4375.
67. Lee, M.-S.; Shin, Y.; Jung, S.; Kim, Y. Effects of epigallocatechin-3-gallate on thermogenesis and mitochondrial biogenesis in brown adipose tissues of diet-induced obese mice. *Food Nutr. Res.* **2017**, *61*, 1325307.
68. Carrera-Quintanar, L.; Lopez Roa, R.I.; Quintero-Fabián, S.; Sánchez-Sánchez, M.A.; Vizmanos, B.; Ortuño-Sahagún, D. Phytochemicals that influence gut microbiota as prophylactics and for the treatment of obesity and inflammatory diseases. *Mediat. Inflamm.* **2018**, *2018*, 9734845. [[CrossRef](#)]
69. Zhang, X.; Zhang, M.; Ho, C.-T.; Guo, X.; Wu, Z.; Weng, P.; Yan, M.; Cao, J. Metagenomics analysis of gut microbiota modulatory effect of green tea polyphenols by high fat diet-induced obesity mice model. *J. Funct. Foods* **2018**, *46*, 268–277.
70. Yen, G.-C.; Cheng, H.-L.; Lin, L.-Y.; Chen, S.-C.; Hsu, C.-L. The potential role of phenolic compounds on modulating gut microbiota in obesity. *J. Food Drug Anal.* **2020**, *28*, 195.
71. Liu, Z.; Chen, Z.; Guo, H.; He, D.; Zhao, H.; Wang, Z.; Zhang, W.; Liao, L.; Zhang, C.; Ni, L. The modulatory effect of infusions of green tea, oolong tea, and black tea on gut microbiota in high-fat-induced obese mice. *Food Funct.* **2016**, *7*, 4869–4879. [[CrossRef](#)]

72. Anhê, F.F.; Roy, D.; Pilon, G.; Dudonné, S.; Matamoros, S.; Varin, T.V.; Garofalo, C.; Moine, Q.; Desjardins, Y.; Levy, E. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. *Gut* **2015**, *64*, 872–883. [[CrossRef](#)]
73. Soeng, S.; Evacuasiyany, E.; Widowati, W.; Fauziah, N.; Manik, V.T.; Maesaroh, M. Inhibitory potential of rambutan seeds extract and fractions on adipogenesis in 3T3-L1 cell line. *J. Exp. Integr. Med.* **2015**, *5*, 55–60. [[CrossRef](#)]
74. Kim, H.-K.; Kim, J.N.; Han, S.N.; Nam, J.-H.; Na, H.-N.; Ha, T.J. Black soybean anthocyanins inhibit adipocyte differentiation in 3T3-L1 cells. *Nutr. Res.* **2012**, *32*, 770–777. [[CrossRef](#)]
75. Pinent, M.; Blade, M.C.; Salvado, M.J.; Arola, L.; Hackl, H.; Quackenbush, J.; Trajanoski, Z.; Ardevol, A. Grape-seed derived procyanidins interfere with adipogenesis of 3T3-L1 cells at the onset of differentiation. *Int. J. Obes.* **2005**, *29*, 934–941.
76. Jiao, X.; Wang, Y.; Lin, Y.; Lang, Y.; Li, E.; Zhang, X.; Zhang, Q.; Feng, Y.; Meng, X.; Li, B. Blueberry polyphenols extract as a potential prebiotic with anti-obesity effects on C57BL/6 J mice by modulating the gut microbiota. *J. Nutr. Biochem.* **2019**, *64*, 88–100. [[CrossRef](#)]
77. Zhou, F.; Guo, J.; Han, X.; Gao, Y.; Chen, Q.; Huang, W.; Zhan, J.; Huang, D.; You, Y. Cranberry polyphenolic extract exhibits an antiobesity effect on high-fat diet-fed mice through increased thermogenesis. *J. Nutr.* **2020**, *150*, 2131–2138. [[CrossRef](#)]
78. van der Zande, H.J.; Lambooi, J.M.; Chavanelle, V.; Zawistowska-Deniziak, A.; Otero, Y.; Otto, F.; Lantier, L.; McGuinness, O.P.; Le Joubioux, F.; Giera, M. Effects of a novel polyphenol-rich plant extract on body composition, inflammation, insulin sensitivity, and glucose homeostasis in obese mice. *Int. J. Obes.* **2021**, *45*, 2016–2027. [[CrossRef](#)]
79. Marimoutou, M.; Le Sage, F.; Smadja, J.; Lefebvre d’Hellencourt, C.; Gonthier, M.-P.; Silva, R.-D. Antioxidant polyphenol-rich extracts from the medicinal plants *Antirhea borbonica*, *Doratoxylon apetalum* and *Gouania mauritiana* protect 3T3-L1 preadipocytes against H₂O₂, TNF α and LPS inflammatory mediators by regulating the expression of superoxide dismutase and NF- κ B genes. *J. Inflamm.* **2015**, *12*, 1–15.
80. Wu, T.; Jiang, Z.; Yin, J.; Long, H.; Zheng, X. Anti-obesity effects of artificial planting blueberry (*Vaccinium ashei*) anthocyanin in high-fat diet-treated mice. *Int. J. Food Sci. Nutr.* **2016**, *67*, 257–264.
81. Kaume, L.; Gilbert, W.C.; Brownmiller, C.; Howard, L.R.; Devareddy, L. Cyanidin 3-O- β -D-glucoside-rich blackberries modulate hepatic gene expression, and anti-obesity effects in ovariectomized rats. *J. Funct. Foods* **2012**, *4*, 480–488.
82. Ikarashi, N.; Toda, T.; Okaniwa, T.; Ito, K.; Ochiai, W.; Sugiyama, K. Anti-obesity and anti-diabetic effects of acacia polyphenol in obese diabetic KKAY mice fed high-fat diet. *Evid.-Based Complement. Altern. Med.* **2011**, *2011*, 952031. [[CrossRef](#)]
83. Dallas, C.; Gerbi, A.; Elbez, Y.; Caillard, P.; Zamaria, N.; Cloarec, M. Clinical study to assess the efficacy and safety of a citrus polyphenolic extract of red Orange, grapefruit, and Orange (Sinetrol-XPur) on weight management and metabolic parameters in healthy overweight individuals. *Phytother. Res.* **2014**, *28*, 212–218. [[CrossRef](#)]
84. Hsu, C.-H.; Tsai, T.-H.; Kao, Y.-H.; Hwang, K.-C.; Tseng, T.-Y.; Chou, P. Effect of green tea extract on obese women: A randomized, double-blind, placebo-controlled clinical trial. *Clin. Nutr.* **2008**, *27*, 363–370. [[CrossRef](#)]
85. Golomb, B.A.; Koperski, S.; White, H.L. Association between more frequent chocolate consumption and lower body mass index. *Arch. Intern. Med.* **2012**, *172*, 519–521.
86. Kim, S.-Y.; Oh, M.-R.; Kim, M.-G.; Chae, H.-J.; Chae, S.-W. Anti-obesity effects of Yerba Mate (*Ilex Paraguariensis*): A randomized, double-blind, placebo-controlled clinical trial. *BMC Complement. Altern. Med.* **2015**, *15*, 1–8.
87. Choquette, S.; Riesco, É.; Cormier, É.; Dion, T.; Aubertin-Leheudre, M.; Dionne, I.J. Effects of soya isoflavones and exercise on body composition and clinical risk factors of cardiovascular diseases in overweight postmenopausal women: A 6-month double-blind controlled trial. *Br. J. Nutr.* **2011**, *105*, 1199–1209. [[CrossRef](#)]
88. Guo, X.; Tresserra-Rimbau, A.; Estruch, R.; Martínez-González, M.A.; Medina-Remón, A.; Fitó, M.; Corella, D.; Salas-Salvadó, J.; Portillo, M.P.; Moreno, J.J. Polyphenol levels are inversely correlated with body weight and obesity in an elderly population after 5 years of follow up (the randomised PREDIMED study). *Nutrients* **2017**, *9*, 452.
89. Basu, A.; Sanchez, K.; Leyva, M.J.; Wu, M.; Betts, N.M.; Aston, C.E.; Lyons, T.J. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. *J. Am. Coll. Nutr.* **2010**, *29*, 31–40. [[CrossRef](#)]
90. Bell, Z.W.; Canale, R.E.; Bloomer, R.J. A dual investigation of the effect of dietary supplementation with licorice flavonoid oil on anthropometric and biochemical markers of health and adiposity. *Lipids Health Dis.* **2011**, *10*, 1–10. [[CrossRef](#)]
91. Kim, J.; Park, J.; Lim, K. Nutrition supplements to stimulate lipolysis: A review in relation to endurance exercise capacity. *J. Nutr. Sci. Vitaminol.* **2016**, *62*, 141–161. [[CrossRef](#)]
92. Rains, T.M.; Agarwal, S.; Maki, K.C. Antiobesity effects of green tea catechins: A mechanistic review. *J. Nutr. Biochem.* **2011**, *22*, 1–7. [[CrossRef](#)]
93. Klaus, S.; Pültz, S.; Thöne-Reineke, C.; Wolfram, S. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. *Int. J. Obes.* **2005**, *29*, 615–623.
94. Murase, T.; Nagasawa, A.; Suzuki, J.; Hase, T.; Tokimitsu, I. Beneficial effects of tea catechins on diet-induced obesity: Stimulation of lipid catabolism in the liver. *Int. J. Obes.* **2002**, *26*, 1459–1464. [[CrossRef](#)]
95. Nabi, B.N.; Sedighinejad, A.; Haghighi, M.; Farzi, F.; Rimaz, S.; Atrkarroushan, Z.; Biazar, G. The Anti-Obesity Effects of Green Tea: A Controlled, Randomized, Clinical Trial. *Iran. Red Crescent Med. J.* **2018**, *20*.
96. Auvichayapat, P.; Prapochanung, M.; Tunkamnerdthai, O.; Sripanidkulchai, B.-O.; Auvichayapat, N.; Thinkhamrop, B.; Kunhasura, S.; Wongpratoom, S.; Sinawat, S.; Hongprapas, P. Effectiveness of green tea on weight reduction in obese Thais: A randomized, controlled trial. *Physiol. Behav.* **2008**, *93*, 486–491.

97. Jiang, H.; Zhang, W.; Li, X.; Xu, Y.; Cao, J.; Jiang, W. The anti-obesogenic effects of dietary berry fruits: A review. *Food Res. Int.* **2021**, *147*, 110539.
98. Stull, A.J.; Cash, K.C.; Johnson, W.D.; Champagne, C.M.; Cefalu, W.T. Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women. *J. Nutr.* **2010**, *140*, 1764–1768.
99. Paquette, M.; Larqué, A.S.M.; Weisnagel, S.; Desjardins, Y.; Marois, J.; Pilon, G.; Dudonné, S.; Marette, A.; Jacques, H. Strawberry and cranberry polyphenols improve insulin sensitivity in insulin-resistant, non-diabetic adults: A parallel, double-blind, controlled and randomised clinical trial. *Br. J. Nutr.* **2017**, *117*, 519–531.
100. Sikora, J.; Broncel, M.; Markowicz, M.; Chałubiński, M.; Wojdan, K.; Mikiciuk-Olasik, E. Short-term supplementation with *Aronia melanocarpa* extract improves platelet aggregation, clotting, and fibrinolysis in patients with metabolic syndrome. *Eur. J. Nutr.* **2012**, *51*, 549–556. [[CrossRef](#)]
101. Lavefve, L.; Howard, L.R.; Carbonero, F. Berry polyphenols metabolism and impact on human gut microbiota and health. *Food Funct.* **2020**, *11*, 45–65.
102. Kim, G.-S.; Park, H.J.; Woo, J.-H.; Kim, M.-K.; Koh, P.-O.; Min, W.; Ko, Y.-G.; Kim, C.-H.; Won, C.-K.; Cho, J.-H. *Citrus aurantium* flavonoids inhibit adipogenesis through the Akt signaling pathway in 3T3-L1 cells. *BMC Complement. Altern. Med.* **2012**, *12*, 1–10. [[CrossRef](#)]
103. Park, J.; Kim, H.-L.; Jung, Y.; Ahn, K.S.; Kwak, H.J.; Um, J.-Y. Bitter orange (*Citrus aurantium* Linné) improves obesity by regulating adipogenesis and thermogenesis through AMPK activation. *Nutrients* **2019**, *11*, 1988. [[CrossRef](#)]
104. Dallas, C.; Gerbi, A.; Tenca, G.; Juchaux, F.; Bernard, F.-X. Lipolytic effect of a polyphenolic citrus dry extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE). *Phytomedicine* **2008**, *15*, 783–792. [[CrossRef](#)]
105. Fukuchi, Y.; Hiramitsu, M.; Okada, M.; Hayashi, S.; Nabeno, Y.; Osawa, T.; Naito, M. Lemon polyphenols suppress diet-induced obesity by up-regulation of mRNA levels of the enzymes involved in β -oxidation in mouse white adipose tissue. *J. Clin. Biochem. Nutr.* **2008**, *43*, 201–209.
106. Harton, A.; Myszkowska-Ryciak, J.; Gajewska, D.; Webb, M. The Role of Selected Bioactive Compounds in Teas, Spices, Cocoa and Coffee in Body Weight Control. *Pol. J. Appl. Sci.* **2017**, *1*, 56–66.
107. Andújar, I.; Recio, M.C.; Giner, R.M.; Ríos, J. Cocoa polyphenols and their potential benefits for human health. *Oxidative Med. Cell. Longev.* **2012**, *2012*, 906252. [[CrossRef](#)]
108. Ferrazzano, G.F.; Amato, I.; Ingenito, A.; De Natale, A.; Pollio, A. Anti-cariogenic effects of polyphenols from plant stimulant beverages (cocoa, coffee, tea). *Fitoterapia* **2009**, *80*, 255–262. [[CrossRef](#)]
109. Shahmohammadi, H.A.; Hosseini, S.A.; Hajiani, E.; Malehi, A.S.; Alipour, M. Effects of green coffee bean extract supplementation on patients with non-alcoholic fatty liver disease: A randomized clinical trial. *Hepat. Mon.* **2017**, *17*.
110. Nordestgaard, A.T.; Thomsen, M.; Nordestgaard, B.G. Coffee intake and risk of obesity, metabolic syndrome and type 2 diabetes: A Mendelian randomization study. *Int. J. Epidemiol.* **2015**, *44*, 551–565. [[CrossRef](#)]
111. Kim, H.-J.; Kim, B.; Mun, E.-G.; Jeong, S.-Y.; Cha, Y.-S. The antioxidant activity of steamed ginger and its protective effects on obesity induced by high-fat diet in C57BL/6J mice. *Nutr. Res. Pract.* **2018**, *12*, 503–511.
112. Suk, S.; Kwon, G.T.; Lee, E.; Jang, W.J.; Yang, H.; Kim, J.H.; Thimmegowda, N.; Chung, M.Y.; Kwon, J.Y.; Yang, S. Gingerenone A, a polyphenol present in ginger, suppresses obesity and adipose tissue inflammation in high-fat diet-fed mice. *Mol. Nutr. Food Res.* **2017**, *61*, 1700139.
113. Ebrahimzadeh Attari, V.; Asghari Jafarabadi, M.; Zemestani, M.; Ostadrahimi, A. Effect of *Zingiber officinale* supplementation on obesity management with respect to the uncoupling protein 1-3826A>G and β 3-adrenergic receptor Trp64Arg polymorphism. *Phytother. Res.* **2015**, *29*, 1032–1039.
114. Park, S.-H.; Jung, S.-J.; Choi, E.-K.; Ha, K.-C.; Baek, H.-I.; Park, Y.-K.; Han, K.-H.; Jeong, S.-Y.; Oh, J.-H.; Cha, Y.-S. The effects of steamed ginger ethanolic extract on weight and body fat loss: A randomized, double-blind, placebo-controlled clinical trial. *Food Sci. Biotechnol.* **2020**, *29*, 265–273.
115. Bucciantini, M.; Leri, M.; Nardiello, P.; Casamenti, F.; Stefani, M. Olive Polyphenols: Antioxidant and Anti-Inflammatory Properties. *Antioxidants* **2021**, *10*, 1044. *Diet. Polyphen. Neuroprotection* **2021**, *71*.
116. Araki, R.; Fujie, K.; Yuine, N.; Watabe, Y.; Nakata, Y.; Suzuki, H.; Isoda, H.; Hashimoto, K. Olive leaf tea is beneficial for lipid metabolism in adults with prediabetes: An exploratory randomized controlled trial. *Nutr. Res.* **2019**, *67*, 60–66.
117. Kandemir, K.; Tomas, M.; McClements, D.J.; Capanoglu, E. Recent advances on the improvement of quercetin bioavailability. *Trends Food Sci. Technol.* **2022**, *119*, 192–200. [[CrossRef](#)]
118. Jakobek, L. Interactions of polyphenols with carbohydrates, lipids and proteins. *Food Chem.* **2015**, *175*, 556–567.
119. Duarte, G.S.; Farah, A. Effect of simultaneous consumption of milk and coffee on chlorogenic acids' bioavailability in humans. *J. Agric. Food Chem.* **2011**, *59*, 7925–7931.
120. Murota, K.; Nakamura, Y.; Uehara, M. Flavonoid metabolism: The interaction of metabolites and gut microbiota. *Biosci. Biotechnol. Biochem.* **2018**, *82*, 600–610.
121. Nagar, E.E.; Okun, Z.; Shpigelman, A. Digestive fate of polyphenols: Updated view of the influence of chemical structure and the presence of cell wall material. *Curr. Opin. Food Sci.* **2020**, *31*, 38–46. [[CrossRef](#)]
122. Lu, Y.; Fan, C.; Li, P.; Lu, Y.; Chang, X.; Qi, K. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota. *Sci. Rep.* **2016**, *6*, 1–13.

123. van der Beek, C.M.; Canfora, E.E.; Kip, A.M.; Gorissen, S.H.; Damink, S.W.O.; van Eijk, H.M.; Holst, J.J.; Blaak, E.E.; Dejong, C.H.; Lenaerts, K. The prebiotic inulin improves substrate metabolism and promotes short-chain fatty acid production in overweight to obese men. *Metabolism* **2018**, *87*, 25–35.
124. Den Besten, G.; Bleeker, A.; Gerding, A.; van Eunen, K.; Havinga, R.; van Dijk, T.H.; Oosterveer, M.H.; Jonker, J.W.; Groen, A.K.; Reijngoud, D.-J. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPAR γ -dependent switch from lipogenesis to fat oxidation. *Diabetes* **2015**, *64*, 2398–2408. [[CrossRef](#)]
125. Weitkunat, K.; Stuhlmann, C.; Postel, A.; Rumberger, S.; Fankhänel, M.; Woting, A.; Petzke, K.J.; Gohlke, S.; Schulz, T.J.; Blaut, M. Short-chain fatty acids and inulin, but not guar gum, prevent diet-induced obesity and insulin resistance through differential mechanisms in mice. *Sci. Rep.* **2017**, *7*, 1–13. [[CrossRef](#)]
126. De la Cuesta-Zuluaga, J.; Mueller, N.T.; Álvarez-Quintero, R.; Velásquez-Mejía, E.P.; Sierra, J.A.; Corrales-Agudelo, V.; Carmona, J.A.; Abad, J.M.; Escobar, J.S. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. *Nutrients* **2018**, *11*, 51. [[CrossRef](#)]
127. Hackman, R.M.; Polagruto, J.A.; Zhu, Q.Y.; Sun, B.; Fujii, H.; Keen, C.L. Flavanols: Digestion, absorption and bioactivity. *Phytochem. Rev.* **2008**, *7*, 195–208. [[CrossRef](#)]
128. Filosa, S.; Di Meo, F.; Crispi, S. Polyphenols-gut microbiota interplay and brain neuromodulation. *Neural Regen. Res.* **2018**, *13*, 2055.
129. Roowi, S.; Stalmach, A.; Mullen, W.; Lean, M.E.; Edwards, C.A.; Crozier, A. Green tea flavan-3-ols: Colonic degradation and urinary excretion of catabolites by humans. *J. Agric. Food Chem.* **2010**, *58*, 1296–1304.
130. Loke, W.M.; Jenner, A.M.; Proudfoot, J.M.; McKinley, A.J.; Hodgson, J.M.; Halliwell, B.; Croft, K.D. A metabolite profiling approach to identify biomarkers of flavonoid intake in humans. *J. Nutr.* **2009**, *139*, 2309–2314.
131. Park, S.; Oh, S.; Kim, T.; Ham, J.; Lee, S. Synthesis of 3,4,5-Trimethoxybenzene Derivatives with Substituted Triazole Group by Huisgen 1,3-Cycloaddition and Their Inhibitory Effects on 3T3-L1 Adipocyte Differentiation. *ChemInform* **2016**, *47*, 1364–1367. [[CrossRef](#)]
132. Aura, A.-M.; O’leary, K.; Williamson, G.; Ojala, M.; Bailey, M.; Puupponen-Pimiä, R.; Nuutila, A.-M.; Oksman-Caldentey, K.-M.; Poutanen, K. Quercetin derivatives are deconjugated and converted to hydroxyphenylacetic acids but not methylated by human fecal flora in vitro. *J. Agric. Food Chem.* **2002**, *50*, 1725–1730.
133. Appeldoorn, M.M.; Vincken, J.-P.; Aura, A.-M.; Hollman, P.C.; Gruppen, H. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl) acetic acid and 5-(3,4-dihydroxyphenyl)- γ -valerolactone as the major metabolites. *J. Agric. Food Chem.* **2009**, *57*, 1084–1092.
134. Coldham, N.; Darby, C.; Hows, M.; King, L.; Zhang, A.-Q.; Sauer, M. Comparative metabolism of genistin by human and rat gut microflora: Detection and identification of the end-products of metabolism. *Xenobiotica* **2002**, *32*, 45–62. [[CrossRef](#)]
135. Hidalgo, M.; Oruna-Concha, M.J.; Kolida, S.; Walton, G.E.; Kallithraka, S.; Spencer, J.P.; de Pascual-Teresa, S. Metabolism of anthocyanins by human gut microflora and their influence on gut bacterial growth. *J. Agric. Food Chem.* **2012**, *60*, 3882–3890. [[CrossRef](#)]
136. Hsu, C.-L.; Huang, S.-L.; Yen, G.-C. Inhibitory effect of phenolic acids on the proliferation of 3T3-L1 preadipocytes in relation to their antioxidant activity. *J. Agric. Food Chem.* **2006**, *54*, 4191–4197.
137. Cerdá, B.; Periago, P.; Espín, J.C.; Tomás-Barberán, F.A. Identification of urolithin A as a metabolite produced by human colon microflora from ellagic acid and related compounds. *J. Agric. Food Chem.* **2005**, *53*, 5571–5576.
138. Xia, B.; Shi, X.C.; Xie, B.C.; Zhu, M.Q.; Chen, Y.; Chu, X.Y.; Cai, G.H.; Liu, M.; Yang, S.Z.; Mitchell, G.A. Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice. *PLoS Biol.* **2020**, *18*, e3000688.
139. Selma, M.V.; Beltrán, D.; García-Villalba, R.; Espín, J.C.; Tomás-Barberán, F.A. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. *Food Funct.* **2014**, *5*, 1779–1784.
140. Serra, A.; Macià, A.; Romero, M.-P.; Reguant, J.; Ortega, N.; Motilva, M.-J. Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. *Food Chem.* **2012**, *130*, 383–393.
141. Rechner, A.R.; Smith, M.A.; Kuhnle, G.; Gibson, G.R.; Debnam, E.S.; Srai, S.K.S.; Moore, K.P.; Rice-Evans, C.A. Colonic metabolism of dietary polyphenols: Influence of structure on microbial fermentation products. *Free. Radic. Biol. Med.* **2004**, *36*, 212–225.
142. Bode, L.M.; Bunzel, D.; Huch, M.; Cho, G.-S.; Ruhland, D.; Bunzel, M.; Bub, A.; Franz, C.M.; Kulling, S.E. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. *Am. J. Clin. Nutr.* **2013**, *97*, 295–309. [[CrossRef](#)]
143. Trinh, H.-T.; Joh, E.-H.; Kwak, H.-Y.; Baek, N.-I.; Kim, D.-H. Anti-pruritic effect of baicalin and its metabolites, baicalein and oroxylin A, in mice. *Acta Pharmacol. Sin.* **2010**, *31*, 718–724.
144. Min, W.; Wu, M.; Fang, P.; Yu, M.; Shi, M.; Zhang, Z.; Bo, P. Effect of baicalein on GLUT4 translocation in adipocytes of diet-induced obese mice. *Cell. Physiol. Biochem.* **2018**, *50*, 426–436. [[CrossRef](#)]
145. Griffiths, L.; Smith, G. Metabolism of apigenin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. *Biochem. J.* **1972**, *128*, 901–911.
146. Hsu, C.-L.; Yen, G.-C. Effects of flavonoids and phenolic acids on the inhibition of adipogenesis in 3T3-L1 adipocytes. *J. Agric. Food Chem.* **2007**, *55*, 8404–8410. [[CrossRef](#)]
147. Kumar Singh, A.; Cabral, C.; Kumar, R.; Ganguly, R.; Kumar Rana, H.; Gupta, A.; Rosaria Lauro, M.; Carbone, C.; Reis, F.; Pandey, A.K. Beneficial effects of dietary polyphenols on gut microbiota and strategies to improve delivery efficiency. *Nutrients* **2019**, *11*, 2216. [[CrossRef](#)]

148. Gonçalves, R.F.; Martins, J.T.; Duarte, C.M.; Vicente, A.A.; Pinheiro, A.C. Advances in nutraceutical delivery systems: From formulation design for bioavailability enhancement to efficacy and safety evaluation. *Trends Food Sci. Technol.* **2018**, *78*, 270–291. [[CrossRef](#)]
149. Sansone, F.; Picerno, P.; Mencherini, T.; Russo, P.; Gasparri, F.; Giannini, V.; Lauro, M.R.; Puglisi, G.; Aquino, R.P. Enhanced technological and permeation properties of a microencapsulated soy isoflavones extract. *J. Food Eng.* **2013**, *115*, 298–305.
150. Papillo, V.A.; Locatelli, M.; Travaglia, F.; Bordiga, M.; Garino, C.; Coisson, J.D.; Arlorio, M. Cocoa hulls polyphenols stabilized by microencapsulation as functional ingredient for bakery applications. *Food Res. Int.* **2019**, *115*, 511–518.
151. Zhou, H.; Zheng, B.; McClements, D.J. In Vitro Gastrointestinal Stability of Lipophilic Polyphenols is Dependent on their Oil–Water Partitioning in Emulsions: Studies on Curcumin, Resveratrol, and Quercetin. *J. Agric. Food Chem.* **2021**, *69*, 3340–3350. [[CrossRef](#)]
152. Ning, P.; Lü, S.; Bai, X.; Wu, X.; Gao, C.; Wen, N.; Liu, M. High encapsulation and localized delivery of curcumin from an injectable hydrogel. *Mater. Sci. Eng. C* **2018**, *83*, 121–129.
153. Wang, L.-C.; Pan, T.-M.; Tsai, T.-Y. Lactic acid bacteria-fermented product of green tea and *Houttuynia cordata* leaves exerts anti-adipogenic and anti-obesity effects. *J. Food Drug Anal.* **2018**, *26*, 973–984. [[CrossRef](#)]
154. Khan, M.K.; Ahmad, K.; Hassan, S.; Imran, M.; Ahmad, N.; Xu, C. Effect of novel technologies on polyphenols during food processing. *Innov. Food Sci. Emerg. Technol.* **2018**, *45*, 361–381.
155. Ofosu, F.K.; Elahi, F.; Daliri, E.B.-M.; Han, S.-I.; Oh, D.-H. Impact of thermal treatment and fermentation by lactic acid bacteria on sorghum metabolite changes, their antioxidant and antidiabetic activities. *Food Biosci.* **2022**, *45*, 101502.
156. Aloo, S.-O.; Ofosu, F.-K.; Daliri, E.-B.-M.; Oh, D.-H. UHPLC-ESI-QTOF-MS/MS metabolite profiling of the antioxidant and antidiabetic activities of red cabbage and broccoli seeds and sprouts. *Antioxidants* **2021**, *10*, 852. [[CrossRef](#)]
157. Lambert, J.D.; Sang, S.; Yang, C.S. Possible controversy over dietary polyphenols: Benefits vs risks. *Chem. Res. Toxicol.* **2007**, *20*, 583–585. [[CrossRef](#)]
158. Bentivegna, S.; Whitney, K. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. *Food Chem. Toxicol.* **2002**, *40*, 1731–1743. [[CrossRef](#)]
159. Mennen, L.I.; Walker, R.; Bennetau-Pelissero, C.; Scalbert, A. Risks and safety of polyphenol consumption. *Am. J. Clin. Nutr.* **2005**, *81*, 326S–329S. [[CrossRef](#)]
160. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. *Cancer Epidemiol. Prev. Biomark.* **2007**, *16*, 1246–1252.
161. Popat, R.; Plesner, T.; Davies, F.; Cook, G.; Cook, M.; Elliott, P.; Jacobson, E.; Gumbleton, T.; Oakervee, H.; Cavenagh, J. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. *Br. J. Haematol.* **2012**, *160*, 714–717. [[CrossRef](#)]
162. Bhatt, J.K.; Thomas, S.; Nanjan, M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. *Nutr. Res.* **2012**, *32*, 537–541. [[CrossRef](#)]
163. Ottaviani, J.I.; Borges, G.; Momma, T.Y.; Spencer, J.P.; Keen, C.L.; Crozier, A.; Schroeter, H. The metabolome of [2-¹⁴C](–)-epicatechin in humans: Implications for the assessment of efficacy, safety and mechanisms of action of polyphenolic bioactives. *Sci. Rep.* **2016**, *6*, 29034.
164. Heber, D.; Seeram, N.P.; Wyatt, H.; Henning, S.M.; Zhang, Y.; Ogden, L.G.; Dreher, M.; Hill, J.O. Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size. *J. Agric. Food Chem.* **2007**, *55*, 10050–10054. [[CrossRef](#)]
165. Chow, H.S.; Cai, Y.; Hakim, I.A.; Crowell, J.A.; Shahi, F.; Brooks, C.A.; Dorr, R.T.; Hara, Y.; Alberts, D.S. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. *Clin. Cancer Res.* **2003**, *9*, 3312–3319.
166. Frank, J.; George, T.W.; Lodge, J.K.; Rodriguez-Mateos, A.M.; Spencer, J.P.; Minihane, A.M.; Rimbach, G. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. *J. Nutr.* **2009**, *139*, 58–62.
167. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med.* **1998**, *64*, 353–356. [[CrossRef](#)]
168. Yoshitomi, R.; Yamamoto, M.; Kumazoe, M.; Fujimura, Y.; Yonekura, M.; Shimamoto, Y.; Nakasone, A.; Kondo, S.; Hattori, H.; Haseda, A. The combined effect of green tea and α -glucosyl hesperidin in preventing obesity: A randomized placebo-controlled clinical trial. *Sci. Rep.* **2021**, *11*, 19067. [[CrossRef](#)]
169. Jamar, G.; Santamarina, A.B.; Flygare, A.C.; Gagliardi, A.; de Rosso, V.V.; Dourado, V.Z.; Pisani, L.P. Effects of the jucara fruit supplementation on metabolic parameters in individuals with obesity: A double-blind randomized controlled trial. *J. Nutr. Biochem.* **2020**, *83*, 108430. [[CrossRef](#)]
170. Boix-Castejón, M.; Herranz-López, M.; Gago, A.P.; Olivares-Vicente, M.; Caturla, N.; Roche, E.; Micol, V. Hibiscus and lemon verbena polyphenols modulate appetite-related biomarkers in overweight subjects: A randomized controlled trial. *Food Funct.* **2018**, *9*, 3173–3184.
171. Serna, A.; Marhuenda, J.; Arcusa, R.; Pérez-Piñeiro, S.; Sánchez-Macarro, M.; Victoria-Montesinos, D.; Cánovas, F.; Jones, J.; Caturla, N.; López-Román, J. Effectiveness of a Polyphenolic Extract (*Lippia Citriodora* and *Hibiscus Sabdariffa*) on Appetite

- Regulation in Overweight and Obese Grade I Population: A 8 weeks Randomized, Double-Blind, Cross-Over, Placebo-Controlled Trial. *Randomized Control. Trial* **2020**, *61*, 825–841. [[CrossRef](#)]
172. Poulsen, M.M.; Vestergaard, P.F.; Clasen, B.F.; Radko, Y.; Christensen, L.P.; Stødkilde-Jørgensen, H.; Møller, N.; Jessen, N.; Pedersen, S.B.; Jørgensen, J.O.L. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. *Diabetes* **2013**, *62*, 1186–1195.
173. Zhang, Y.; Yu, Y.; Li, X.; Meguro, S.; Hayashi, S.; Katashima, M.; Yasumasu, T.; Wang, J.; Li, K. Effects of catechin-enriched green tea beverage on visceral fat loss in adults with a high proportion of visceral fat: A double-blind, placebo-controlled, randomized trial. *J. Funct. Foods* **2012**, *4*, 315–322.
174. Baba, A.; Hoshino, T.; Ogawa, S.; Takara, T. Improvement of glucose metabolism and safety of acacia bark-derived proanthocyanidins in healthy Japanese adults: A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial. *Funct. Foods Health Dis.* **2021**, *11*, 431–455.
175. Roberts, A.T.; Martin, C.K.; Liu, Z.; Amen, R.J.; Woltering, E.A.; Rood, J.C.; Caruso, M.K.; Yu, Y.; Xie, H.; Greenway, F.L. The safety and efficacy of a dietary herbal supplement and gallic acid for weight loss. *J. Med. Food* **2007**, *10*, 184–188. [[CrossRef](#)]
176. Ifie, I.; Marshall, L.J. Food processing and its impact on phenolic constituents in food. *Cogent Food Agric.* **2018**, *4*, 1507782. [[CrossRef](#)]
177. Dao, L.; Friedman, M. Chlorogenic acid content of fresh and processed potatoes determined by ultraviolet spectrophotometry. *J. Agric. Food Chem.* **1992**, *40*, 2152–2156.
178. Pandey, K.B.; Rizvi, S.I. Plant polyphenols as dietary antioxidants in human health and disease. *Oxidative Med. Cell. Longev.* **2009**, *2*, 270–278. [[CrossRef](#)]
179. Ou, J.; Wang, M.; Zheng, J.; Ou, S. Positive and negative effects of polyphenol incorporation in baked foods. *Food Chem.* **2019**, *284*, 90–99. [[CrossRef](#)]
180. Aloo, S.O.; Mwititi, G.; Ngugi, L.W.; Oh, D.-H. Uncovering the secrets of industrial hemp in food and nutrition: The trends, challenges, and new-age perspectives. *Crit. Rev. Food Sci. Nutr.* **2022**, 1–20. [[CrossRef](#)]
181. Shen, P.; Gao, Z.; Fang, B.; Rao, J.; Chen, B. Ferreting out the secrets of industrial hemp protein as emerging functional food ingredients. *Trends Food Sci. Technol.* **2021**, *112*, 1–15. [[CrossRef](#)]
182. Spencer, J.P.; Abd El Mohsen, M.M.; Minihane, A.-M.; Mathers, J.C. Biomarkers of the intake of dietary polyphenols: Strengths, limitations and application in nutrition research. *Br. J. Nutr.* **2008**, *99*, 12–22.
183. Cory, H.; Passarelli, S.; Szeto, J.; Tamez, M.; Mattei, J. The role of polyphenols in human health and food systems: A mini-review. *Front. Nutr.* **2018**, *5*, 87.
184. Hursel, R.; Viechtbauer, W.; Westerterp-Plantenga, M.S. The effects of green tea on weight loss and weight maintenance: A meta-analysis. *Int. J. Obes.* **2009**, *33*, 956–961.
185. D'Archivio, M.; Filesi, C.; Vari, R.; Scazzocchio, B.; Masella, R. Bioavailability of the polyphenols: Status and controversies. *Int. J. Mol. Sci.* **2010**, *11*, 1321–1342.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.